notificationsアラート設定
~
検索条件をクリア

アブストラクト

Title アトピー性皮膚炎診療ガイドライン2021
Subtitle ガイドライン
Authors 一般社団法人日本アレルギー学会 公益社団法人日本皮膚科学会 アトピー性皮膚炎診療ガイドライン作成委員会
Authors (kana)
Organization
Journal アレルギー
Volume 70
Number 10
Page 1257-1342
Year/Month 2021 /
Article 報告
Publisher 日本アレルギー学会
Abstract 「第I章」「1. はじめに」アトピー性皮膚炎は日常診療で頻繁に遭遇する疾患である. これまで国内には, アトピー性皮膚炎の診療においてプライマリーケアの段階から高度の専門性が要求される段階までの患者を診療する, 皮膚科診療を専門とする医師を対象として作成された日本皮膚科学会アトピー性皮膚炎診療ガイドラインと, 皮膚科以外のアレルギー疾患の診療に関わる医師, 関連領域の医療従事者を対象として作成された厚生労働省研究班および日本アレルギー学会の診療ガイドラインがあった. 2018年にこれらの2つの診療ガイドラインを統合し, アトピー性皮膚炎の患者の診療に関わるすべての医師, 医療従事者を対象とした診療ガイドラインが作成された. 今回のアトピー性皮膚炎診療ガイドラインは, 国内外で発表されたアトピー性皮膚炎に関する新しい知見を加えて作成された改訂版である.
Practice 臨床医学：内科系
Keywords
download正誤表(0.94MB)
  • 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
download全文ダウンロード(28.70MB)

参考文献

  • 1) 川島 眞, 瀧川雅浩, 中川秀己ほか : 日本皮膚科学会編「アトピー性皮膚炎治療ガイドライン」, 日皮会誌, 2000 ; 110 : 1099-1104.
  • 2) 古江増隆, 古川福実, 秀 道広, 竹原和彦 : 日本皮膚科学会アトピー性皮膚炎治療ガイドライン2003改訂版, 日皮会誌, 2003 ; 113 : 451-457.
  • 3) 古江増隆, 古川福実, 秀 道広, 竹原和彦 : 日本皮膚科学会アトピー性皮膚炎治療ガイドライン2004改訂版, 日皮会誌, 2004 ; 114 : 135-142.
  • 4) 古江増隆, 佐伯秀久, 古川福実ほか : 日本皮膚科学会アトピー性皮膚炎診療ガイドライン, 日皮会誌, 2008 ; 118 : 325-342.
  • 5) 古江増隆, 佐伯秀久, 古川福実ほか : 日本皮膚科学会アトピー性皮膚炎診療ガイドライン, 日皮会誌, 2009 ; 119 : 1515-1534.
残りの498件を表示する
  • 6) 加藤則人, 佐伯秀久, 中原剛士ほか : アトピー性皮膚炎診療ガイドライン2016年版, 日皮会誌, 2016 ; 126 : 121-155.
  • 7) 河野陽一, 山本昇壯 : アトピー性皮膚炎治療ガイドライン, 厚生労働科学研究, 1999.
  • 8) 古江増隆, 山本昇壯 : アトピー性皮膚炎治療ガイドライン, 厚生労働科学研究, 2001.
  • 9) 山本昇壮, 河野陽一監修 : アトピー性皮膚炎治療ガイドライン2005, 厚生労働科学研究, 2005.
  • 10) 山本昇壮, 河野陽一監修, 日本アレルギー学会 : アトピー性皮膚炎診療ガイドライン2006, 東京, 協和企画, 2006.
  • 11) 片山一朗, 河野陽一監修, 日本アレルギー学会 : アトピー性皮膚炎診療ガイドライン2009, 東京, 協和企画, 2009.
  • 12) 片山一朗, 河野陽一監修, 日本アレルギー学会 : アトピー性皮膚炎診療ガイドライン2012, 東京, 協和企画, 2012.
  • 13) 片山一朗, 河野陽一監修, 日本アレルギー学会 : アトピー性皮膚炎診療ガイドライン2015, 東京, 協和企画, 2015.
  • 14) 加藤則人, 大矢幸弘, 池田政憲ほか : アトピー性皮膚炎診療ガイドライン2018, 日皮会誌, 2018 ; 128 : 2431-2502.
  • 15) 鼻アレルギー診療ガイドライン作成委員会 : 鼻アレルギー診療ガイドライン2020年版, 東京, ライフサイエンス, 2020.
  • 16) Elias PM : Stratum corneum defensive func-tions : an integrated view, J Invest Dermatol, 2005 ; 125 : 183-200.
  • 17) Melnik B, Hollmann J, Plewig G : Decreased stra-tum corneum ceramidcs in atopic individuals--a pathobiochemical factor in xerosis? Br J Dermatol, 1988 ; 119 : 547-549.
  • 18) Cabanillas B, Novak N : Atopic dermatitis and filaggrin, Curr Opin Immunol, 2016 ; 42 : 1-8.
    pubmed
  • 19) Kono M, Nomura T, Ohguchi Y, et al : Compre-hensive screening for a complete set of Japa-nese-population-specific filaggrin gene mutations, Allergy, 2014 ; 69 : 537-540.
  • 20) De Benedetto A, Rafaels NM, McGirt LY, et al : Tight junction defects in patients with atopic dermatitis, J Allergy Clin Immunol, 2011 ; 127 : 773-786.
    pubmed
  • 21) Tokumasu R, Yamaga K, Yamazaki Y, et al : Dose-dependent role of claudin-1 in vivo inorchestrating features of atopic dermatitis, Proc Natl Acad Sci USA, 2016 12 ; 113 : E4061-4068.
  • 22) Fujita H, Nograles KE, Kikuchi T, Gonzalez J, Carucci JA, Krueger JG : Human Langerhans cells induce distinct IL-22-producing CD4+ T cells lacking IL-17 production, Proc Natl Acad Sci USA, 2009 ; 106 : 21795-21800.
    pubmed
  • 23) Hammad H, Lambrecht BN : Barrier epithelial cells and the control of type 2 immunity. Immu-nity, 2015 ; 43 : 29-40.
  • 24) Murota H, Katayama I : Exacerbating factors of itch in atopic dermatitis, Allergol Int, 2017 ; 66 : 8-13.
    pubmed
  • 25) 上出良一 : 痒みの評価. 日皮会誌, 2005 ; 115 : 1764-1770.
  • 26) Papoiu AD, Wang H, Coghill RC, et al : Conta-gious itch in humans : a study of visual'trans-mission'of itch in atopic dermatitis and healthy subjects, Br J Dermatol, 2011 ; 164 : 1299-303.
  • 27) Ikoma A, Fartasch M, Heyer G, et al : Painful stimuli evoke itch in patients with chronic pruri-tus : central sensitization for itch, Neurology, 2004 ; 27 : 212-217.
  • 28) Murota H, Katayama I : Evolving understanding on the aetiology of thermally provoked itch, Eur J Pain, 2016 ; 20 : 47-50.
    pubmed
  • 29) 室田浩之 : 体性感覚と痒み, 皮膚臨床, 2020 ; 62 : 435-443.
  • 30) Sonkoly E, Muller A, Lauerma AI, et al : IL-31 : a new link between T cells and pruritus in atopic skin inflammation, J Allergy Clin Immunol, 2006 ; 117 : 411-417.
    pubmed
  • 31) Oetjen LK, Mack MR, Feng J, et al : Sensory neurons co-opt classical immune signaling path-ways to mediate chronic itch, Cell, 2017 ; 171 : 217-228.
  • 32) Shiratori-Hayashi M, Koga K, Tozaki-Saitoh H, et al : STAT3-dependent reactive astrogliosis in the spinal dorsal horn underlies chronic itch, Nat Med, 2015 ; 21 : 927-931.
    pubmed
  • 33) Tominaga M, Takamori K : Itch and nerve fibers with special reference to atopic dermatitis : ther-apeutic implications, J Dermatol, 2014 ; 41 : 205-212.
  • 34) Azimi E, Reddy VB, Pereira PJS, et al : Sub-stance P activates Mas-related G protein-coupled receptors to induce itch, J Allergy Clin Immunol, 2017 ; 140 : 447-453. e3.
  • 35) Hirota T, Takahashi A, Kubo M, et al : Genome-wide association study identifies eight new sus-ceptibility loci for atopic dermatitis in the Japanese population, Nat Genet, 2012 ; 44 : 1222-1226.
  • 36) Wahlgren CF : Itch and atopic dermatitis : clini-cal and experimental studies, Acta Derm Venereol Suppl(Stockh), 1991 ; 165 : 1-53.
  • 37) Williams H, Robertson C, Stewart A, et al : Worldwide variations in the prevalence of symp-toms of atopic eczema in the International Study of Asthma and Allergies in Childhood, J Allergy Clin Immunol, 1999 ; 103 : 125-138.
  • 38) Williams H, Stewart A, von Mutius E, et al : Is eczema really on the increase worldwide? J Allergy Clin Immunol, 2008 ; 121 : 947-954.
    pubmed
  • 39) 森田栄伸 : アトピー性皮膚炎患者数の実態, 原因・悪化因子に関する資料の解析・整理, 平成13年度厚生科学研究費補助金 : 免疫・アレルギー等研究事業研究報告書 : 第2分冊, 2002 : 184-186.
  • 40) 山本昇壯 : アトピー性皮膚炎の患者数の実態及び発症・悪化に及ぼす環境因子の調査に関する研究. 平成14年度厚生労働科学研究費補助金 : 免疫アレルギー疾患予防・治療研究事業研究報告書 : 第1分冊, 2003 : 71-77.
  • 41) Saeki H, Iizuka H, Mori Y, et al : Prevalence of atopic dermatitis in Japanese elementary school-children, Br J Dermatol, 2005 ; 152 : 110-114.
    pubmed
  • 42) Saeki H, Oiso N, Honma M, et al : Prevalence of atopic dermatitis in Japanese adults and commu-nity validation of the U.K. diagnostic criteria, J Dermatol Sci, 2009 ; 55 : 140-141.
  • 43) 上田 宏 : アトピー性皮膚炎の疫学, 小児内科, 2000 ; 32 : 986-992.
  • 44) 三河春樹 : アレルギー疾患の疫学研究, 厚生省アレルギー総合研究事業総合研究報告書, 1995 : 247-251.
  • 45) 太田國隆, 岡 尚記, 岡崎 薫ほか : 西日本小学児童におけるアレルギー疾患有症率調査-1992年と2002年の比較-, 日小ア誌, 2003 ; 17 : 255-268.
  • 46) Kusunoki T, Morimoto T, Nishikomori R, et al : Changing prevalence and severity of childhood allergic diseases in Kyoto, Japan, from 1996 to 2006, Allergol Int, 2009 ; 58 : 543-548.
    pubmed
  • 47) Ricci G, Patrizi A, Baldi E, et al : Long-term fol-low-up of atopic dermatitis : retrospective analy-sis of related risk factors and association with concomitant allergic diseases, J Am Acad Derma-tol, 2006 ; 55 : 765-771.
  • 48) Illi S, von Mutius E, Lau S, et al : The natural course of atopic dermatitis from birth to age 7 years and the association with asthma, J Allergy Clin Immunol, 2004 ; 113 : 925-931.
    pubmed
  • 49) Sandstrom MH, Faergemann J : Prognosis and prognostic factors in adult patients with atopic dermatitis : a longterm follow-up questionnaire study, Br J Dermatol, 2004 ; 150 : 103-110.
  • 50) 河野陽一 : アトピー性皮膚炎の発症および悪化因子の同定と発症予防・症状悪化防止のための生活環境整備に関する研究, 平成18〜20年度総合研究報告書, 2009 : 1-11.
  • 51) Fukiwake N, Furusyo N, Kubo N, et al : Inci-dence of atopic dermatitis in nursery school chil-dren-a follow-up study from 2001 to 2004, Kyushu University Ishigaki Atopic Dermatitis Study(KIDS), Eur J Dermatol, 2006 ; 16 : 416-419.
  • 52) Ohshima Y, Yamada A, Hiraoka M, et al : Early sensitization to house dust mite is a major risk factor for subsequent development of bronchial asthma in Japanese infants with atopic dermati-tis : results of a 4-year followup study, Ann Allergy Asthma Immunol, 2002 ; 89 : 265-270.
  • 53) 渋谷紀子, 斉藤恵美子 : 抗原感作およびアレルギー疾患の自然経過-4歳までの出生コホート研究, 日小ア誌, 2015 ; 29 : 284-293.
    Medical*Online
  • 54) Yamamoto-Hanada K, Yang L, Saito-Abe M, et al : Four phenotypes of atopic dermatitis in Jap-anese children : A general population birth cohort study, Allergol Int, 2019 ; 68 : 521-523.
  • 55) Yamamoto-Hanada K, Pak K, Saito-Abe M, et al : Allergy and immunology in young children of Japan : The JECS cohort, World Allergy Organ J, 2020 ; 13 : 100479.
  • 56) 阿南貞雄, 山本憲嗣 : アトピー性皮膚炎の自然緩解について, 皮膚, 1996 ; 38(Suppl. 18) : 13-16.
  • 57) Wakamori T, Katoh N, Hirano S, et al : Atopic dermatitis, dry skin and serum IgE in children in a community in Japan, Int Arch Allergy Immu-nol, 2009 ; 149 : 103-110.
  • 58) Katoh N, Hirano S, Kishimoto S : Prognostic fac-tor of adult patients with atopic dermatitis, J Dermatol, 2008 ; 35 : 477-483.
  • 59) Hanifin JM, Rajka G : Diagnostic features of atopic dermatitis, Acta Derm-Venereol(Stockh), 1980 ; 92(Suppl) : 44-47.
  • 60) Williams HC, Burney PGJ, Pembroke AC, Hay RJ : The UK Working Party's Diagnostic criteria for atopic dermatitis. III. Independent hospital validation, Br J Dermatol, 1994 ; 131 : 406-416.
  • 61) Aoki T, Fukuzumi J, Adachi J, et al. : Re-evalua-tion of skin lesion distribution in atopic dermati-tis, Acta Derm Venereol(Stockh), 1992 ; 176(Suppl) : 19-23.
  • 62) Hsu AP, Davis J, Puck JM, MD, Holland SM, Freeman AF : STAT3 Hyper IgE Syndrome, http://www.ncbi.nlm.nih.gov/books/NBK25507/
  • 63) 青木敏之 : アトピー性皮膚炎重症度分類検討委員会 第2次報告書, 日皮会誌, 2001 ; 111 : 2023-2033.
  • 64) 吉田彦太郎 : アトピー性皮膚炎重症度分類検討委員会からの中間報告, 日皮会誌, 1998 ; 108 : 1491-1496.
  • 65) Severity scoring of atopic dermatitis : the SCORAD index. Consensus Report of the Euro-pean Task Force on Atopic Dermatitis, Derma-tology, 1993 ; 186 : 23-31.
  • 66) Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M : The eczema area and severity index(EASI) : assessment of reliability in atopic dermatitis. EASI Evaluator Group, Exp Dermatol, 2001 ; 10 : 11-18.
    pubmed
  • 67) Eichenfield LF, Tom WL, Berger TG, et al : Guidelines of care for the management of atopic dermatitis : part 2. Management and treatment of atopic dermatitis with topical therapies, J Am Acad Dermatol, 2014 ; 71 : 116-132.
  • 68) 川島 眞, 原田昭太郎, 丹後俊郎 : そう痒の程度の新しい判定基準を用いた患者日誌の使用経験, 臨皮, 2002 ; 56 : 692-697.
  • 69) 江畑俊哉, 石氏陽三, 佐伯秀久, 中川秀己 : 5D itch scale日本語版の作成, 日皮会誌, 2015 ; 125 : 1035-1040.
  • 70) Murray CS, Rees JL : Are subjective accounts of itch to be relied on? The lack of relation between visual analogue itch scores and acti-graphic measures of scratch, Acta Derm Venereol, 2011 ; 91 : 18-23.
  • 71) Ikoma A, Ebata T, Chantalat L, et al : Measure-ment of nocturnal scratching in patients with pruritus using a smartwatch : Initial clinical studies with the itch tracker app, Acta Derm Venereol, 2019 ; 99 : 268-273.
  • 72) Noro Y, Omoto Y, Umeda K, et al : Novel acous-tic evaluation system for scratching behavior in itching dermatitis : rapid and accurate analysis for nocturnal scratching of atopic dermatitis patients, J Dermatol, 2014 ; 41 : 233-238.
  • 73) Charman CR, Venn AJ, Williams HC : The patient-oriented eczema measure : development and initial validation of a new tool for measuring atopic eczema severity from the patients' per-spective, Arch Dermatol, 2004 ; 140 : 1513-1519.
  • 74) Charman CR, Venn AJ, Ravenscroft. JC, Williams HC : Translating Patient-Oriented Eczema Mea-sure(POEM)scores into clinical practice by suggesting severity strata derived using anchor-based methods, Br J Dermatol, 2013 ; 169 : 1326-1332.
  • 75) Gaunt DM, Metcalfe C, Ridd M : The Patient-Ori-ented Eczema Measure in young children : responsiveness and minimal clinically important difference, Allergy, 2016 ; 71 : 1620-1625.
  • 76) Stalder JF, Barbarot S, Wollenberg A, et al : Patient-Oriented SCORAD(PO-SCORAD) : a new self-assessment scale in atopic dermatitis validated in Europe, Allergy, 2011 ; 66 : 1114-1121.
    pubmed
  • 77) Howells L, Chalmers JR, Gran S, et al : Develop-ment and initial testing of a new instrument to measure the experience of eczema control in adults and children : Recap of atopic eczema(RECAP), Br J Dermatol, 2020 ; 183 : 524-536.
  • 78) Pariser DM, Simpson EL, Gadkari A, et al : Eval-uating patient-perceived control of atopic derma-titis : design, validation, and scoring of the Atopic Dermatitis Control Tool(ADCT), Curr Med Res Opin, 2019 ; 12 : 1-10.
  • 79) Thomas KS, Apfelbacher CA, Chalmers JR, et al : Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials : results of the HOME VII consensus meeting, Br J Derma-tol, 2021 ; doi : 10.1111/bjd.19751.
  • 80) Takahashi N, Suzukamo Y, Nakamura M, et al : Acne QOL questionnaire development team. Japanese version of the Dermatology Life Qual-ity Index : validity and reliability in patients with acne, Health Quul Life Outcomes, 2006 ; 4 : 46.
    pubmed
  • 81) 福原俊一, 鈴鴨よしみ. DLQI日本語版とSkin-dex-29日本語版. アレルギーの臨床, 2007 ; 358 : 23-7.
  • 82) Higaki Y, Kawamoto K, Kamo T, Horikawa N, Kawashima M, Chren MM : The Japanese ver-sion of Skindex-16 : a brief quality-of-life measure for patients with skin diseases, J Dermatol, 2002 ; 29 : 693-698.
  • 83) 大矢幸弘, 佐々木りか子, 松本美江子ほか : 小児アトピー性皮膚炎QOL評価尺度(CDLQI)日本語版の開発, アレルギー, 2002 ; 51 : 265.
    Medical*Online
  • 84) Lewis-Jones MS, Finlay AY : The Children's Der-matology Life Quality Index(CDLQI) : initial validation and practical use, Br J Dermatol, 1995 ; 132 : 942-949.
  • 85) Kondo-Endo K, Ohashi Y, Nakagawa H, et al : Development and validation of a questionnaire measuring quality of life in primary caregivers of children with atopic dermatitis(QPCAD), Br J Dermatol, 2009 ; 161 : 617-625.
    pubmed
  • 86) 勝沼俊雄, 丹 愛子, 大矢幸弘 : 小児アトピー性皮膚炎患者養育者のQuality of Life調査票短縮版(QP9)の開発と臨床的評価, アレルギー, 2013 ; 62 : 33-46.
    Medical*Online
  • 87) Chamlin SL, Cella D, Frieden IJ, et al : Develop-ment of the Childhood Atopic Dermatitis Impact Scale : initial validation of a quality-of-life mea-sure for young children with atopic dermatitis and their families, J Invest Dermatol, 2005 ; 125 : 1106-1111.
  • 88) Yamaguchi C, Futamura M, Chamlin SL, Ohya Y, Asano M : Development of a Japanese Cultur-ally Modified Version of the Childhood Atopic Dermatitis Impact Scale(JCMV-CADIS). Aller-gol Int, 2016 ; 65 : 312-319.
  • 89) Smith PH, Ownby DR : Clinical significance of immunoglobulin E. In : Adkinson NF Jr, Bochner BS, Burks AW, et al, eds : Middleton's Allergy ; Principles and Practice, Philadelphia : Mosby ; 2014 : 1108-1119.
  • 90) Saeki H, Tamaki K : Thymus and activation reg-ulated chemokine(TARC) /CCL17 and skin dis-eases, J Dermatol Sci, 2006 ; 43 : 75-84.
  • 91) 玉置邦彦, 佐伯秀久, 門野岳史ほか : アトピー性皮膚炎の病勢指標としての血清TARC/CCL17値についての臨床的検討, 日皮会誌, 2006 ; 116 : 27-39.
  • 92) 藤澤隆夫, 長尾みづほ, 野間雪子ほか : 小児アトピー性皮膚炎の病勢評価マーカーとしての血清TARC/CCL17の臨床的有用性, 日小ア誌, 2005 ; 19 : 744-757.
  • 93) Kataoka Y : Thymus and activation-regulated chemokine as a clinical biomarker in atopic der-matitis, J Dermatol, 2014 ; 41 : 221-229.
  • 94) Fujisawa T, Nagao M, Hiraguchi Y, et al : Serum measurement of thymus and activation-regu-lated chemokine/CCL17 in children with atopic dermatitis : elevated normal levels in infancy and age-specific analysis in atopic dermatitis, Pediatr Allergy Immunol, 2009 ; 20 : 633-641.
  • 95) Bartuski AJ, Kamachi Y, Schick C, Overhauser J, Silvermanet GA : Cytoplasmic antiproteinase 2(PI8)and bomapin(PI10)map to the serpin cluster at 18q21.3, Genomics, 1997 ; 43 : 321-328.
  • 96) Kato H, Torigoe T : Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma, Cancer, 1977 ; 40 : 1621-1628.
    pubmed
  • 97) Nagao M, Inagaki S, Kawano T, et al : SCCA2 is a reliabte biomarker for evaluating pediatric atopic dermatitis, J Allergy Clin Immunol, 2018 ; 141 : 1934-1936. e11.
  • 98) Okawa T, Yamaguchi Y, Kou K, et al : Serum levels of squamous cell carcinoma antigens 1 and 2 reflect disease severity and clinical type of atopic dermatitis in adult patients, Allergol Int, 2018 ; 67 : 124-130.
    pubmed
  • 99) Sivaprasad U, Kinker KG, Ericksen MB, et al : SERPINB3/B4 contributes to early inflammation and barrier dysfunction in an experimental murine model of atopic dermatitis, J Invest Der-matol, 2015 ; 135 : 160-169.
  • 100) Takeuchi S, Furusyo N, Ono J, et al : Serum squamous cell carcinoma antigen(SCCA) -2 cor-relates with clinical severity of pediatric atopic dermatitis in Ishigaki cohort, J Dermatol Sci, 2019 ; 95 : 70-75.
  • 101) Yuyama N, Davies DE, Akaiwa M, et al : Analy-sis of novel disease-related genes in bronchial asthma, Cytokine, 2002 ; 19 : 287-296.
  • 102) Hepburn DJ, Aeling JL, Weston WL : A reap-praisal of topical steroid potency, Pediatr Derma-tol, 1996 ; 13 : 239-245.
  • 103) Hoare C, Li Wan Po A, Williams H : Systematic review of treatments for atopic eczema, Health Technol Assess, 2000 ; 4 : 1-191.
    pubmed
  • 104) http://www.nice.org.uk/guidance/ta81/resources/guidance Frequency of application of topical cor-ticosteroids for atopic eczema. In : National Insti-tute for Health and Care Excellence Guidance. 2004.
  • 105) Long CC, Finlay AY : The finger-tip unit-a new practical measure, Clin Exp Dermatol, 1991 ; 16 : 444-447.
    pubmed
  • 106) Long CC, Finlay AY, Averill RW : The rule of hand : 4hand area=2 FTU=1g, Arch Dermatol, 1992 ; 128 : 1129-1130.
  • 107) Green C, Colquitt JL, Kirby J, Davidson P : Top-ical corticosteroids for atopic eczema : clinical and cost effectiveness of once-daily vs. more fre-quent use, Br J Dermatol, 2005 ; 152 : 130-141.
  • 108) Green C, Colquitt JL, Kirby J, Davidson P, Payne E : Clinical and cost-effectiveness of once-daily versus more frequent use of same potency topi-cal corticosteroids for atopic eczema : a system-atic review and economic evaluation, Health Technol Assess, 2004 ; 8 : 1-120.
  • 109) Feldman RJ, Maibach HI : Regional variation in percutaneous penetration of 14C cortisol in man, J Invst Dermatol, 1967 ; 48 : 181-183.
  • 110) Hajar T, Lesham YA, Hanifin JM, et al : A sys-tematic review of topical corticosteroid with-drawal("steroid addiction")in patients with atopic dermatitis and other dermatoses, J Am Acad Dermatol, 2015 ; 72 : 541-549.
  • 111) Coondoo A, Phiske M, Verma S, Lahiri K : Side-effects of topical steroids : A long overdue revisit. Indian Dermatol Online J, 2014 ; 5 : 416-425.
    pubmed
  • 112) Hengge UR, Ruzicka T, Schwartz RA, Cork MJ : Adverse effects of topical glucocorticoste-roids, J Am Acad Dermatol, 2006 ; 54 : 1-15.
  • 113) Haeck IM, Hamdy NA, Timmer-de Mik L, et al : Low bone mineral density in adult patients with moderate to severe atopic dermatitis, Br J Derma-tol 2009 ; 161 : 1248-1254.
  • 114) Vestergaard P : Skeletal effects of systemic and topical corticosteroids. Curr Drug Saf. 2008 ; 3 : 190-193.
    pubmed
  • 115) van Velsen SG, Knol MJ, van Eijk RL, et al : Bone mineral density in children with moderate to severe atopic dermatitis, J Am Acad Dermatol, 2010 ; 63 : 824-831.
    pubmed
  • 116) 古江増隆 : ステロイド外用薬の使い方 : コツと落とし穴, アレルギー, 2009 ; 58 : 491-497.
    Medical*Online
  • 117) Takeda K, Arase S, Takahashi S : Side effects of topical corticosteroids and their prevention, Drugs, 1988 ; 36(Suppl 5) : 15-23.
  • 118) 武田克之, 原田種雄, 安里哲時, 石本彰宏, 野本正志, 倉本昌明 : 副腎皮質ホルモン外用剤の全身に及ぼす影響-特に副腎機能抑制を中心に, 医学のあゆみ, 1977 ; 101 : 817-829.
  • 119) 島尾周平 : 皮膚科領域におけるステロイド療法とその問題点-特にその副作用を中心として-. 西日皮膚, 40 : 5-24, 1978.
  • 120) Wood Heickman LK, Davallow Ghajar L, Conaway M, Rogol AD : Evaluation of hypotha-lamic-pituitary-adrenal axis suppression follow-ing cutaneous use of topical corticosteroids in children : A meta-analysis, Horm Res Paediatr, 2018 ; 89 : 389-396.
  • 121) Abraham A, Roga G : Topical steroid-damaged skin, Indian J Dermatol, 2014 ; 59 : 456-459.
    pubmed
  • 122) Furue M, Terao H, Rikihisa W, et al : Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis, Br J Der-matol, 2003 ; 148 : 128-33.
  • 123) Furue M, Terao H, Moroi Y, et al : Dosage and adverse effects of topical tacrolimus and steroids in daily management of atopic dermatitis, J Der-matol, 2004 ; 31 : 277-283.
  • 124) Beck KM, Seitzman GD, Yang EJ, Sanchez IM, Liao W : Ocular co-morbidities of atopic dermati-tis. Part II : Ocular disease secondary to treat-ments, Am J Clin Dermatol, 2019 ; 20 : 807-815.
  • 125) Hsu JI, Pflugfelder SC, Kim SJ : Ocular complica-tions of atopic dermatitis, Cutis, 2019 ; 104 : 189-193.
  • 126) 中野栄子, 岩崎琢也, 小山内卓哉, 山本和則, 宮内 恵 : アトピー性皮膚炎の眼合併症, 日眼会誌, 1997 : 101 : 64-68.
  • 127) 中川直之, 塚原祐子, 鉄本員章 : アトピー性白内障に関する臨床的危険因子の統計学的検討, あたらしい眼科, 2000 ; 17 : 1679-1684.
  • 128) Yamamoto K, Wakabayashi Y, Kawakami S, et al : Recent trends of ocular complications in patients with atopic dermatitis. Jpn J Ophthalmol, 2019 ; 63 : 410-416.
    pubmed
  • 129) 後藤 浩, 真田彰郎, 若林美宏ほか : アトピー白内障の成因としての外傷の意義, あたらしい眼科, 1996 ; 13 : 1728-1732.
  • 130) 平野眞也, 加藤則人, 安野洋一 : 予後からみた成人型アトピー性皮膚炎の重症度の解析, 日皮会誌, 1995 ; 10 : 1309-1315.
  • 131) 古江増隆, 川島 眞, 古川福実ほか : アトピー性皮膚炎患者における前向きアンケート調査(第2報), 臨皮, 2011 ; 65 : 83-92.
  • 132) Taniguchi H, Ohki O, Yokozeki H, et al : Cata-ract and retinal detachment in patients with severe atopic dermatitis who were withdrawn from the use of topical corticosteroid, J Dermatol, 1999 ; 26 : 658-665.
  • 133) 内山賢美, 杉浦久嗣, 上原正巳, 中村二郎, 可児一孝 : アトピー性白内障 : 最近の発生状況と白内障誘発因子について, 皮膚臨床, 1996 ; 38, 61-64.
  • 134) 有川順子, 檜垣祐子, 高村悦子, 川島 眞 : アトピー性皮膚炎患者の眼圧と顔面へのステロイド外用療法との関連性についての検討, 日皮会誌, 2002 ; 112 : 1107-1110.
  • 135) FK506軟膏研究会 : アトピー性皮膚炎におけるタクロリムス軟膏0.1%および0.03%の使用ガイダンス, 臨皮, 2003 ; 57 : 1217-1234.
  • 136) Arellano FM, Wentworth CE, Arana A, Fernan-dez C, Paul CF : Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis, J Invest Dermatol, 2007 ; 127 : 808-816.
  • 137) Schneeweiss S, Doherty M, Zhu S, et al. : Topical treatments with pimecrolimus, tacrolimus and medium-to high-potency corticosteroids, and risk of lymphoma, Dermatology, 2009 ; 219 : 7-21.
    pubmed
  • 138) マルホ株式会社2019年5月. プロトピック(R)軟膏0.03%小児用 製造販売後調査集計結果のお知らせ
  • 139) Nakagawa H, Nemoto O, Igarashi A, Nagata T : Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis : a phase II, multicentre, randomized, vehicle-controlled clini-cal study, Br J Dermatol, 2018 ; 178 : 424-432.
  • 140) Nakagawa H, Nemoto O, Igarashi A, Saeki H, Kaino H, Nagata T. Delgocitinib ointment, a topi-cal Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis : A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study, J Am Acad Dermatol, 2020 ; 82 : 823-831.
  • 141) Nakagawa H, Nemoto O, Igarashi A, et al : Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis, J Dermatol, 2020 ; 47 : 114-120.
    pubmed
  • 142) 中村晃一郎, 二村昌樹, 常深祐一郎, 種瀬啓士, 加藤則人 : デルゴシチニブ軟膏(コレクチム(R)軟膏0.5%)安全使用マニュアル, 日皮会誌, 2020 ; 130 : 1581-1588.
  • 143) Ring J, Alomar A, Bieber T, et al : Guidelines for treatment of atopic eczema(atopic dermatitis)Part II, J Eur Acad Dermatol Venereol, 2012 ; 26 : 1176-1193.
  • 144) Caproni M, Torchia D, Antiga E, et al : The com-parative effects of tacrolimus and hydrocorti-sone in adult atopic dermatitis : an immunohistochemical study, Br J Dermatol, 2007 ; 156 : 312-319.
  • 145) Simon D, Vassina E, Yousefi S, Kozlowski E, Braathen LR, Simon HU : Reduced dermal infil-tration of cytokine-expressing inflammatory cells in atopic dermatitis after short-term topical tac-rolimus treatment, J Allergy Clin Immunol, 2004 ; 114 : 887-895.
  • 146) Schmitt J, von Kobyletzki L, Svensson A, Apfel-bacher C : Efficacy and tolerability of proactive treatment with topical corticosteroids and calci-neurin inhibitors for atopic eczema : systematic review and meta-analysis of randomized con-trolled trials, Br J Dermatol, 2011 ; 164 : 415-428.
  • 147) Saito R, Tanaka A, Hiragun T, et al : Reduction of serum thymus and activation-regulated chemokine after short-term intensive therapy may predict better prognosis of moderate to severe atopic dermatitis, J Dermatol, 2019 ; 46 : e486-e487.
    pubmed
  • 148) Matterne U, Bohmer MM, Weisshaar E, Jupiter A, Carter B, Apfelbacher CJ : Oral H1 antihista-mines as'add-on'therapy to topical treatment for eczema, Cochrane Database Syst Rev, 2019 ; CD012167.
  • 149) Apfelbacher CJ, van Zuuren EJ, Fedorowicz Z, Jupiter A, Matterne U, Weisshaar E : Oral H1 antihistamines as monotherapy for eczema, Cochrane Database Syst Rev, 2013 ; CD007770.
    pubmed
  • 150) 谷内一彦 : 薬理作用から見た理想的な抗ヒスタミン薬治療, 日耳鼻, 2020 ; 123 : 196-204.
  • 151) Schmitt J, Schmitt N, Meurer M : Cyclosporin in the treatment of patients with atopic eczema-a systematic review and meta-analysis, J Eur Acad Dermatol Venereol, 2007 ; 21 : 606-619.
    pubmed
  • 152) ネオーラルによるアトピー性皮膚炎治療研究会 : 成人の重症アトピー性皮膚炎患者に対するシクロスポリンMEPC 間歇投与法の安全性および有効性評価 : 多施設共同, オープン, 長期間観察試験, 臨皮, 2009 ; 63 : 163-171.
  • 153) Kim JE, Shin JM, Ko JY, Ro YS : Importance of concomitant topical therapy in moderate-to-se-vere atopic dermatitis treated with cyclosporine, Dermatol Ther, 2016 ; 29 : 120-125.
  • 154) Hashizume H, Ito T, Yagi H, et al : Efficacy and safety of preprandial versus postprandial admin-istration of low-dose cyclosporin microemulsion(Neoral)in patients with psoriasis vulgaris, J Dermatol, 2007 ; 34 : 430-434.
  • 155) Cheng HM, Chiang LC, Jan YM, Chen GW, Li TC : The efficacy and safety of a Chinese herbal product(Xiao-Feng-San)for the treatment of refractory atopic dermatitis : a randomized, dou-ble-blind, placebo-controlled trial, Int Arch Allergy Immunol, 2011 ; 155 : 141-148.
  • 156) Kobayashi H, Ishii M, Takeuchi S, et al : Efficacy and safety of a traditional herbal medicine, Hochu-ekki-to in the long-term management of Kikyo(delicate constitution)patients with atopic dermatitis : a 6-month, multicenter, double-blind, randomized, placebo-controlled study, Evid Based Complement Alternat Med, 2010 ; 7 : 367-373.
  • 157) Sheehan MP, Atherton DJ : A controlled trial of traditional Chinese medicinal plants in wide-spread non-exudative atopic eczema, Br J Derma-tol, 1992 ; 126 : 179-184.
  • 158) Sheehan MP, Rustin MHA, Atherton DJ, et al. : Efficacy of traditional Chinese herbal therapy in adult atopic dermatitis, Lancet, 1992 ; 340 : 13-17.
  • 159) Fung AYP, Look PCN, Chong LY, But PPH, Wong E : A controlled trial of traditional Chinese herbal medicine in Chinese patients with recalci-trant atopic dermatitis, Int J Dermatol, 1999 ; 38 : 387-392.
  • 160) O'Shea JJ, Plenge R : JAKs and STATs in immu-noregulation and immune-mediated disease, Immunity, 2012 ; 36 : 542-550.
  • 161) Simpson EL, Lacour JP, Spelman L, et al : Baric-itinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids : results from two randomized monotherapy phase III trials, Br J Dermatol, 2020 ; 183 : 242-255.
  • 162) Guttman-Yassky E, Silverberg JI, Nemoto O, et al : Baricitinib in adult patients with moder-ate-to-severe atopic dermatitis : A phase 2 paral-lel, double-blinded, randomized placebo-controlled multiple-dose study, J Am Acad Dermatol, 2019 ; 80 : 913-921.
  • 163) Reich K, Kabashima K, Peris K, et al : Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis : A randomized clinical trial, JAMA Dermatol, 2020 ; 156 : 1333-1343.
    pubmed
  • 164) Bieber T, Thyssen JP, Reich K, et al : Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clini-cal trials, J Eur Acad Dermatol Venereol, 2021 ; 35 : 476-485.
  • 165) 厚生労働省 : 最適使用推進ガイドライン バリシチニブ(販売名 : オルミエント錠2mg, オルミエント錠4mg)〜アトピー性皮膚炎〜. https://www.pmda.go.jp/files/000238112.pdf
  • 166) 厚生労働省保険局医療課長 : ヤヌスキナーゼ阻害薬に係る最適使用推進ガイドラインの策定に伴う留意事項について, 保医発1225第3号, 令和2年12月25日
  • 167) Chang HY, Nadeau KC : IL-4Ra inhibitor for atopic disease, Cell, 2017 ; 170 : 222.
    pubmed
  • 168) Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD : Targeting key proxi-mal drivers of type 2 inflammation in disease, Nat Rev Drug Discov, 2016 ; 15 : 35-50.
  • 169) Langan SM, Irvine AD, Weidinger S : Atopic dermatitis, Lancet, 2020 ; 396 : 345-360.
    pubmed
  • 170) Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD : Atopic dermatitis, Nat Rev Dis Prim-ers, 2018 ; 4 : 1.
    pubmed
  • 171) Boguniewicz M, Leung DY : Atopic dermatitis : a disease of altered skin barrier and immune dysregulation. Immunol Rev, 2011 ; 242 : 233-246.
    pubmed
  • 172) Thaci D, Simpson EL, Beck LA, et al : Efficacy and safety of dupilumab in adults with moder-ate-to-severe atopic dermatitis inadequately con-trolled by topical treatments : a randomised, placebo-controlled, dose-ranging phase 2b trial, Lancet, 2016 ; 387 : 40-52.
  • 173) Simpson EL, Bieber T, Guttman-Yassky E, et al : Two phase 3 trials of dupilumab versus pla-cebo in atopic dermatitis. N Engl J Med, 2016 ; 375 : 2335-2348.
  • 174) Worm M, Simpson EL, Thaci D, et al : Efficacy and safety of multiple dupilumab dosc regimens after initial successful treatment in patients with atopic dermatitis : A randomized clinical trial, JAMA Dermatol, 2020 ; 156 : 131-143.
  • 175) Blauvelt A, de Bruin-Weller M, Gooderham M, et al : Long-term management of moderate-to-se-vere atopic dermatitis with dupilumab and con-comitant topical corticosteroids(LIBERTY ADCHRONOS) : a 1-year, randomised, dou-ble-blinded, placebo-controlled, phase 3 trial, Lan-cet, 2017 ; 389 : 2287-2303.
  • 176) Deleuran M, Thaci D, Beck LA, et al : Dupi-lumab shows long-term safety and efficacy in patients with moderate to severe atopic dermati-tis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol, 2020 ; 82 : 377-388.
  • 177) de Bruin-Weller M, Thaci D, Smith CH, et al : Dupilumab with concomitant topical corticoste-roid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medi-cally inadvisable : a placebo-controlled, random-ized phase III clinical trial(LIBERTY ADCAFE). Br J Dermatol, 2018 ; 178 : 1083-1101.
  • 178) Beck LA, Thaci D, Deleuran M, et al : Dupi-lumab provides favorable safety and sustained efficacy for up to 3 years in an open-label study of adults with moderate-to-severe atopic derma-titis, Am J Clin Dermatol, 2020 ; 21 : 567-577.
  • 179) Wollenberg A, Barbarot S, Bieber T, et al : Con-sensus-based European guidelines for treatment of atopic eczema(atopic dermatitis)in adults and children : part II. J Eur Acad Dermatol Venereol, 2018 ; 32 : 850-878.
  • 180) Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR : Atopic derma-titis yardstick : Practical recommendations for an evolving therapeutic landscape, Ann Allergy Asthma Immunol, 2018 ; 120 : 10-22, e2.
  • 181) Damiani G, Calzavara-Pinton P, Stingeni L, et al : Italian guidelines for therapy of atopic der-matitis-adapted from consensus-based European guidelines for treatment of atopic eczema(atopic dermatitis), Dermatol Ther, 2019 ; 32 : e13121.
  • 182) 厚生労働省 最適使用推進ガイドライン デュピルマブ(遺伝子組換え)(販売名 : デュピクセント皮下注300mgシリンジ, 同皮下注300mgペン)〜アトピー性皮膚炎〜平成30年4月(令和2年11月改訂)https://www.pmda.go.jp/files/000237673.pdf
  • 183) 厚生労働省保険局医療課長 : 抗IL-4受容体αサブユニット抗体製剤に係る最適使用推進ガイドラインの策定に伴う留意事項について, 保医発0417第5号, 平成30年4月17日
  • 184) 厚生労働省保険局医療課長 : 抗IL-4受容体αサブユニット抗体製剤に係る最適使用推進ガイドラインの策定に伴う留意事項の一部改正について, 保医発0326第3号, 平成31年3月26日
  • 185) 厚生労働省保険局医療課長 : 療担規則及び薬担規則並びに療担基準に基づき厚生労働大臣が定める掲示事項等の一部改正等について, 保医発0426第3号, 平成31年4月26日
  • 186) Beck KM, Seitzman GD, Yang EJ, Sanchez IM, Liao W : Ocular co-morbidities of atopic dermati-tis. Part II : Ocular disease secondary to treat-ments, Am J Clin Dermatol, 2019 ; 20 : 807-815.
  • 187) Akinlade B, Guttman-Yassky E, de Bruin-Weller M, et al : Conjunctivitis in dupilumab clinical tri-als, Br J Dermatol, 2019 ; 181 : 459-473.
  • 188) Thyssen JP, de Bruin-Weller MS, Paller AS, et al : Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy-interna-tional eczema council survey and opinion, J Eur Acad Dermatol Venereol, 2019 ; 33 : 1224-1231.
  • 189) Mygind H, Thulstrup AM, Pedersen L, Larsen H : Risk of intrauterine growth retardation, mal-formations and other birth outcomes in children after topical use of corticosteroid in pregnancy, Acta Obstet Gynecol Scand, 2002 ; 81 : 234-239.
  • 190) Czeizel AE, Rockenbauer M : Population-based case-control study of teratogenic potential of cor-ticosteroids, Teratology, 1997 ; 56 : 335-340.
  • 191) Chi CC, Wang SH, Wojnarowska F, Kirtschig G, Davies E, Bennett C : Safety of topical corticoste-roids in pregnancy. Cochrane Database Syst Rev, 2015 ; CD007346.
  • 192) Chi CC, Wang SH, Kirtschig G : Safety of topical corticosteroids in pregnancy, JAMA Dermatol, 2016 ; 152 : 934-935.
    pubmed
  • 193) Chi CC, Mayon-White RT, Wojnarowska FT : Safety of topical corticosteroids in pregnancy : a population-based cohort study, J Invest Dermatol, 2011 ; 131 : 884-891.
    pubmed
  • 194) Chi CC, Wang SH, Mayon-White R Wojn-arowska F : Pregnancy outcomes after maternal exposure to topical corticosteroids : a UK popu-lation-based cohort study, JAMA Dermatol, 2013 ; 149 : 1274-1280.
  • 195) Chi CC, Kirtschig G, Aberer W, et al : Updated evidence-based(S2e)European Dermatology Forum guideline on topical corticosteroids in pregnancy, J Eur Acad Dermatol Venereol, 2017 ; 31 : 761-773.
    pubmed
  • 196) Jain A, Venkataramanan R, Fung JJ, et al : Preg-nancy after liver transplantation under tacroli-mus, Transplantation, 1997 ; 64 : 559-565.
  • 197) Loden M, Andersson AC, Andersson C, et al. : A double-blind study comparing the effect of glyc-erin and urea on dry, eczematous skin in atopic patients, Acta Derm Venereol, 2002 ; 82 : 45-47.
  • 198) 川島 眞, 沼野香世子, 石崎千明 : アトピー性皮膚炎患者の皮膚生理学的機能異常に対する保湿剤の有用性, 日皮会誌, 2007 ; 117 : 969-977.
  • 199) van Zuuren EJ, Fedorowicz Z, Christensen R, et al : Emollients and moisturisers for eczema, Cochrane Database Sys Rev, 2017 ; CD012119.
  • 200) 大谷真理子, 大谷道輝, 野澤 茜ほか : 保湿剤の効果に及ぼす塗布量および塗布回数の検討, 日皮会誌, 2012 ; 122 : 39-43.
  • 201) 中村光裕, 上村康二, 根本 治, 宮地良樹 : 保湿剤の至適外用方法の検討, 皮膚の科学, 2006 ; 5 : 311-316.
  • 202) Werner Y, Lindberg M : Transepidermal water loss in dry and clinically normal skin in patients with atopic dermatitis, Acta Derm Venereol, 1985 ; 65 : 102-105.
    pubmed
  • 203) 川島 眞, 林 伸和, 乃木田俊辰, 柳澤恭子, 水野惇子 : アトピー性皮膚炎の寛解維持における保湿剤の有用性の検討, 日皮会誌, 2007 ; 117 : 1139-1145.
  • 204) Denda M, Sokabe T, Fukumi-Tominaga T, Tomi-naga M : Effects of skin surface temperature on epidermal permeability barrier homeostasis, J Invest Dermatol, 2007 ; 127 : 654-659.
  • 205) Ikoma A, Fartasch M, Heyer G, Miyachi Y, Handwerker, Schmelz M : Painful stimuli evoke itch in patients with chronic pruritus : central sensitization for itch, Neurology, 2004 ; 62 : 212-217.
    pubmed
  • 206) Murota H, Izumi M, Abd El-Latif MI, et al : Artemin causes hypersensitivity to warm sensa-tion, mimicking warmth-prevoked pruritus in atopic dermatitis, J Allergy Clin Immunol, 2012 ; 130 : 671-682.
  • 207) Cheng X, Jin J, Hu L, et al : TRP channel regu-lates EGFR signaling in hair morphogenesis and skin barrier formation. Cell, 2010 ; 141 : 331-343.
  • 208) Uehara M, Takada K : Use of soap in the man-agement of atopic dermatitis, Clin Exp Dermatol, 1985 ; 10 : 419-425.
  • 209) 上原正巳 : アトピー性皮膚炎における入浴時の石鹸使用について, 皮膚臨床, 1981 ; 23 : 1049-1052.
  • 210) Fonacier LS, Aquino MR : The role of contact allergy in atopic dermatitis, Immunol Allergy Clin North Am, 2010 ; 30 : 337-350.
    pubmed
  • 211) Giordano-Labadie F, Rance F, Pellegrin F, Bazex J, Dutau G, Schwarze HP : Frequency of contact allergy in children with atopic dermatitis : results of a prospective study of 137 cases, Con-tact Dermatitis, 1999 ; 40 : 192-195.
  • 212) Tamagawa-Mineoka R, Masuda K, Ueda S, et al : Contact sensitivity in patients with recalci-trant atopic dermatitis, J Dermatol, 2015 ; 42 : 720-722.
  • 213) 高山かおる, 横関博雄, 松永佳世子ほか : 接触皮膚炎診療ガイドライン2020, 日皮会誌, 2020 ; 130 : 523-567.
  • 214) Bath-Hextall F, Delamere FM, Williams HC : Dietary exclusions for established atopic eczema, Cochrane Database Syst Rev, 2008 ; CD005203.
    pubmed
  • 215) Kramer MS, Kakuma R : Maternal dietary anti-gen avoidance during pregnancy or lactation, or both, for preventing or treating atopic disease in the child, Cochrane Database Syst Rev, 2012 ; CD000133.
  • 216) Schafer T, Heinrich J, Wjst M, Adam H, Ring J, Wichmann HE : Association between severity of atopic eczema and degree of sensitization to aeroallergens in schoolchildren, J Allergy Clin Immunol, 1999 ; 104 : 1280-1284.
    pubmed
  • 217) Sulzberger MB, Herrmann F, Zak FG : Studies of sweating ; preliminary report with particular emphasis of a sweat retention syndrome, J Invest Dermatol, 1947 ; 9 : 221-242.
    pubmed
  • 218) Shiohara T, Doi T, Hayakawa J : Defective sweating responses in atopic dermatitis, Curr probl Dermatol, 2011 ; 41 : 68-79.
    pubmed
  • 219) Eishi K, Lee JB, Bae SJ, Takenaka M, Katayama I : Impaired sweating function in adult atopic dermatitis : results of the quantitative sudomo-tor axon reflex test, Br J Dermatol, 2001 ; 147 : 683-688.
  • 220) Kijima A, Murota H, Matsui S, et al : Abnormal axon reflex-mediated sweating correlates with high state of anxiety in atopic dermatitis, Allergol Int, 2012 ; 61 : 469-473.
    pubmed
  • 221) Takahashi A, Murota H, Matsui S, et al : Decreased sudomotor function is involved in the formation of atopic eczema in the cubital fossa, Allergol Int, 2013 ; 62 : 473-478.
    pubmed
  • 222) Yamaga K, Murota H, Tamura A, et al : Clau-din-3 loss causes leakage of sweat from the sweat gland to contribute to the pathogenesis of atopic dermatitis, J Invest Dermatol, 2018 ; 138 : 1279-1287.
  • 223) Hiragun T, Ishii K, Hiragun M, et al : Fungal protein MGL_1304 in sweat is an allergen for atopic dermatitis patients, J Allergy Clin Immunol, 2013 ; 132 : 608-615.
    pubmed
  • 224) Imayama S, Shimozono Y, Hoashi M, et al : Reduced secretion of IgA to skin surface of patients with atopic dermatitis, J Allergy Clin Immunol, 1994 ; 94 : 195-200.
    pubmed
  • 225) Rieg S, Steffen H, Seeber S, et al : Deficiency of dermcidin-derived antimicrobial peptides in sweat of patients with atopic dermatitis cor-relates with an impaired innate defense of human skin in vivo, J Immunol, 2005 ; 174 : 8003-8010.
  • 226) Ono E, Murota H, Mori Y, et al : Sweat glucose and GLUT2 expression in atopic dermatitis : Implication for clinical manifestation and treat-ment, PLoS One, 2018 ; 13 : e0195960.
  • 227) Murota H, Katayama I : Lifestyle guidance for pediatric patients with atopic dermatitis based on age specific physiological function of skin, Pediatr Allergy Immunol Pulmonol, 2016 ; 29 : 196-201.
    pubmed
  • 228) Kong HH, Oh J, Derming C, et al : Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis, Genome Res, 2012 ; 22 : 850-859.
  • 229) Harkins CP, Pettigrew KA, Oravcova K, et al : The microevolution and epidemiology of Staphy-lococcus aureus colonization during atopic eczema disease flare, J Invest Dermatol, 2018 ; 138 : 336-343.
  • 230) Kobayashi T, Glatz M, Horiuchi K, et al : Dysbio-sis and Staphylococcus aureus colonization drives inflammation in atopic dermatitis, Immunity, 2015 ; 42 : 756-766.
  • 231) Bath-Hextall FJ, Birnie AJ, Ravenscroft JC, Wil-liams HC : Interventions to reduce Staphylococcus aureus in the management of atopic eczema : an updated Cochrane review, Br J Dermatol, 2010 ; 163 : 12-26.
  • 232) Savolainen J, Lammintausta K, Kalimo K, Vian-der M : Candida albicans and atopic dermatitis, Clin Exp Allergy, 1993 ; 23 : 332-339.
  • 233) Takechi M : Minimum effective dosage in the treatment of chronic atopic dermatitis with itraconazole, J Int Med Res, 2005 ; 33 : 273-283.
    pubmed
  • 234) Mayser P, Kupfer J, Nemetz D, et al : Treatment of head and neck dermatitis with ciclopiroxol-amine cream--results of a double-blind, place-bo-controlled study, Skin Pharmacol Physiol, 2006 ; 19 : 153-158.
  • 235) 大矢幸弘 : アレルギー疾患の心身医学-古典から現代へ-. 心身医学, 2018 ; 58 : 376-383.
    Medical*Online
  • 236) Horev A, Freud T, Manor I, Cohen AD, Zvu-lunov A : Risk of attention-deficit /hyperactivity disorder in children with atopic dermatitis, Acta Dermatovenerol Croat, 2017 ; 25 : 210-214.
  • 237) Mochizuki H, Tanaka S, Morita T, Wasaka T, Sadato N, Kakigi R : The cerebral representation of scratching-induced pleasantness, J Neuro-physiol, 2014 ; 111 : 488-498.
  • 238) Arakawa H, Shimojo N, Katoh N, et al : Consen-sus statements on pediatric atopic dermatitis from dermatology and pediatrics practitioners in Japan : Goals of treatment and topical therapy, Allergol Int, 2020 ; 69 : 84-90.
  • 239) Lack G, Fox D, Northstone K, et al. : Factors associated with the development of peanut allergy in childhood, N Engl J Med, 2003 ; 348 : 977-985.
    pubmed
  • 240) Lack G : Epidemiologic risks for food allergy, J Allergy Clin Immunol, 2008 ; 122 : 984-991.
    pubmed
  • 241) Tsakok T, Marrs T, Mohsin M, et al : Does atopic dermatitis cause food allergy? A system-atic review, J Allergy Clin Immunol, 2016 ; 137 : 1071-1078.
  • 242) Miyaji Y, Yang L, Yamamoto-Hanada K, Narita M, Saito H, Ohya Y : Earlier aggressive treat-ment to shorten the duration of eczema in infants resulted in fewer food allergies at 2 years of age, J Allergy Clin Immunol Pract, 2020 ; 8 : 1721-1724. e6.
  • 243) Simpson EL, Chalmers JR, Hanifin JM, et al : Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis preven-tion, J Allergy Clin Immunol, 2014 ; 134 : 818-823.
  • 244) Horimukai K, Morita K, Narita M, et al : Applica-tion of moisturizer to neonates prevents devel-opment of atopic dermatitis, J Allergy Clin Immunol, 2014 ; 134 : 824-830.
  • 245) Natsume O, Kabashima S, Ohya Y : Two-step egg introduction for preventing egg allergy in high-risk Infants with eczema(PETIT study) : a double-blind, placebo-controlled, parallel-group randomized clinical trial, Lancet, 2017 ; 389 : 276-286.
  • 246) 福家辰樹, 大矢幸弘, 海老澤元宏ほか : 鶏卵アレルギー発症予防に関する提言, 日小ア会誌, 2017 ; 31 : i-x.
  • 247) 日本小児アレルギー学会 : 食物アレルギー診療ガイドライン2016, 東京, 協和企画, 2016.
  • 248) 太田國雄, 岡 尚記, 岡崎 薫 : 西日本小学児童におけるアレルギー疾患有症率調査 1992年と2002年の比較, 日小ア会誌, 2003 ; 17 : 255-268.
  • 249) 飯倉洋治, 小田島安平, 北林 耐ら : スギ花粉と種々のアレルギー症状との関係, アレルギー・免疫, 2002 ; 9 : 343-349.
  • 250) Werfel T, Heratizadeh A, Niebuhr M, et al. : Exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge cham-ber, J Allergy Clin Immunol, 2015 ; 136 : 96-103.
  • 251) Beck KM, Seitzman GD, Yang EJ, Sanchez IM, Liao W : Ocular co-morbidities of atopic dermati-tis. Part I : Associated ocular diseases, Am J Clin Dermatol, 2019 ; 20 : 797-805.
  • 252) Hsu JI, Pflugfelder SC, Kim SJ : Ocular complica-tions of atopic dermatitis, Cutis, 2019 ; 104 : 189-193.
  • 253) Thyssen JP, Toft PB, Halling-Overgaard AS, Gis-lason GH, Skov L, Egeberg A : Incidence, preva-lence, and risk of selected ocular disease in adults with atopic dermatitis, J Am Acad Dermatol, 2017 ; 77 : 280-286.
  • 254) Beck KM, Seitzman GD, Yang EJ, Sanchez IM, Liao W : Ocular co-morbidities of atopic dermati-tis. Part II : Ocular disease secondary to treat-ments, Am J Clin Dermatol, 2019 ; 20 : 807-815.
  • 255) Eriksson B, Jorup-Ronstrom C, Karkkonen K, Sjoblom AC, Holm SE : Erysipelas : clinical and bacteriologic spectrum and serological aspects, Clin Infect Dis, 1996 ; 23 : 1091-1098.
    pubmed
  • 256) Gunderson CG, Martinello RA : A systematic review of bacteremias in cellulitis and erysipelas, J Infect, 2012 ; 64 : 148-155.
    pubmed
  • 257) Sidbury R, Davis DM, Cohen DE, et al : Guide-lines of care for the management of atopic der-matitis. Section 3. Management and treatment with phototherapy and systemic agents, J Am Acad Dermatol, 2014 ; 71 : 327-349.
  • 258) Wollenberg A, Barbarot S, Bieber T, et al : Con-sensus-based European guidelines for treatment of atopic eczema(atopic dermatitis)in adults and children : part I, J Eur Acad Dermatol Venereol, 2018 ; 32 : 657-682.
  • 259) Garritsen FM, Brouwer MW, Limpens J, Spuls PI : Photo(chemo)therapy in the management of atopic dermatitis : an updated systematic review with implications for practice and research, Br J Dermatol, 2014 ; 170 : 501-513.
    pubmed
  • 260) 森田明理, 江藤隆史, 鳥居秀嗣ほか : 乾癬の光線療法ガイドライン, 日皮会誌, 2016 ; 126 : 1239-1262.
  • 261) 向井秀樹, 福田英嗣, 鈴木 琢, 早乙女敦子, 早出恵理 : アトピー性皮膚炎の入院療法の有用性アンケート調査による皮膚および精神症状の改善度の検討, 皮膚の科学, 2012 ; 11(Suppl 18) : 43-47.
  • 262) 片岡葉子 : アトピー性皮膚炎診療の質QIを考える, Visual Dermatology, 2014 ; 13 : 1094-1097.
  • 263) Staab D, Diepgen TL, Fartasch M, et al : Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents : multicentre, randomised con-trolled trial, BMJ, 2006 ; 332 : 933-938.
  • 264) Moore EJ, Williams A, Manias E, Varigos G, Donath S : Eczema workshops reduce severity of childhood atopic eczema, Australas J Dermatol, 2009 ; 50 : 100-106.
    pubmed
  • 265) Futamura M, Masuko I, Hayashi K, Ohya Y, Ito K : Effects of a short-term parental education program on childhood atopic dermatitis : a ran-domized controlled trial, Pediatr Dermatol, 2013 ; 30 : 438-443.
  • 266) Armstrong AW, Kim RH, Idriss NZ, Larsen LN, Lio PA : Online video improves clinical outcomes in adults with atopic dermatitis : a randomized controlled trial, J Am Acad Dermatol, 2011 ; 64 : 502-507.
    pubmed
  • 267) Ersser SJ, Cowdell F, Latter S, et al : Psycholog-ical and educational interventions for atopic eczema in children, Cochrane Database Syst Rev, 2014 ; CD004054.
  • 268) 九州大学皮膚科学教室 : 「アトピー性皮膚炎についていっしょに考えましょう.」. https://www.kyudai-derm.org/atopy/index.html.2013
  • 269) 独立行政法人環境再生保全機構 : 「ぜん息悪化予防のための小児アトピー性皮膚炎ハンドブック」. https://www.erca.go.jp/yobou/pamphlet/form/00/archives_1028.html.2009
  • 270) Bjorksten B, Naaber P, Sepp E, et al : The intes-tinal microflora in allergic Estonian and Swedish 2-year-old children, Clin Exp Allergy, 1999 ; 29 : 342-346.
  • 271) Panduru M, Panduru NM, Salavastru CM, et al : Probiotics and primary prevention of atopic der-matitis : a meta-analysis of randomized con-trolled studies. J Eur Acad Dermatol Venereol, 2015 ; 29 : 232-242.
  • 272) Jiang W, Ni B, Liu Z, et al : The role of probiotics in the prevention and treatment of atopic der-matitis in children : An updated systematic review and meta-analysis of randomized con-trolled trials, Paediatr Drugs, 2020 ; 22 : 535-549.
  • 273) Cuello-Garcia C, Fiocchi A, Pawankar R, et al : Prebiotics for the prevention of allergies : A sys-tematic review and meta-analysis of randomized controlled trials, Clin Exp Allergy, 2017 ; 47 : 1468-1477.
  • 274) Chang YS, Trivedi MK, Jha A, Lin YF, Dimaano L, Garcia-Romero MT : Synbiotics for prevention and treatment of atopic dermatitis : A meta-anal-ysis of randomized clinical trials, JAMA Pediatr, 2016 ; 170 : 236-242.
  • 275) Makrgeorgou A, Leonardi-Bee J, Bath-Hextall FJ, et. al : Probiotics for treating eczema, Cochrane Database Syst Rev, 2018 ; CD006135.
  • 276) Koga Y, Tokunaga S, Nagano J, et al : Age-asso-ciated effect of kestose on Faecalibacterium prausnitzii and symptoms in the atopic dermati-tis infants, Pediatr Res, 2016 ; 80 : 844-851.
  • 277) Shibata R, Kimura M, Takahashi H, et al : Clini-cal effects of kestose, a prebiotic oligosaccharide, on the treatment of atopic dermatitis in infants, Clin Exp Allergy, 2009 ; 39 : 1397-1403.
  • 278) Bozensky J, Hill M, Zelenka R, Skyba T : Prebi-otics do not influence the severity of atopic der-matitis in infants : A randomised controlled trial, PLoS One, 2015 ; 10 : e0142897.
  • 279) 秀 道広, 山村有美, 森田栄伸, 高路 修, 山本昇壯 : アトピー性皮膚炎に対する民間療法の実態調査, 西日皮膚, 2000 ; 62 : 83-88.
  • 280) Sato M, Yamamoto-Hanada K, Yang L, et al : Complementary and alternative medicine and atopic dermatitis in children. J Dermatol Sci, 2020 ; 97 : 80-82.
  • 281) Kojima R, Fujiwara T, Matsuda A, et al : Factors associated with steroid phobia in caregivers of children with atopic dermatitis, Pediatr dermatol, 2013 ; 30 : 29-35.
    pubmed
  • 282) 竹原和彦, 飯塚 一, 伊藤雅章ほか : アトピー性皮膚炎における不適切治療による健康被害の実態調査[最終報告], 日皮会誌, 2000 ; 110 : 1095-1098.
  • 283) Pfab F, Huss-Marp J, Gatti A, et al : Influence of acupuncture on type I hypersensitivity itch and the wheal and flare response in adults with atopic eczema-a blinded, randomized, place-bo-controlled, crossover trial, Allergy, 2010 ; 65 : 903-910.
  • 284) Siebenwirth J, Luedtke R, Remy W, Rakoski J, Borelli S, Ring J : Effectiveness of a classical homeopathic treatment in atopic eczema. A ran-domised placebo-controlled double-blind clinical trial, Forsch Komplementmed, 2009 ; 16 : 315-323.
  • 285) World Health Organization : Adherence to long-term therapies-Evidence for action. 2003 ; http://whqlibdoc.who.int/publications/2003/9241545992.pdf
  • 286) Eicher L, Knop M, Aszodi N, Senner S, French LE, Wollenberg A : A systematic review of fac-tors influencing treatment adherence in chronic inflammatory skin disease-strategies for optimiz-ing treatment outcome, J Eur Acad Dermatol Vene-reol, 2019 ; 33 : 2253-2263.
  • 287) Ascertaining barriers for compliance : policies for safe, effective and costeffective use of medi-cines in Europe. Final report of the ABC project 2012 ; Available at : http://www.ABCproject.eu
  • 288) Ou HT, Feldman SR, Balkrishnan R : Under-standing and improving treatment adherence in pediatric patients, Semin Cutan Med Surg, 2010 ; 29 : 137-140.
  • 289) 益子育代 : 患者教育総論, 日本小児難治喘息・アレルギー疾患学会 : 小児アレルギーエデュケーターテキスト・実践編. 東京, 診断と治療社 : 2013 ; 1-24.
  • 290) Armstrong AW, Johnson MA, Lin S, Maverakis E, Fazel N, Liu FT : Patient-centered, direct-ac-cess online care for management of atopic der-matitis : a randomized clinical trial, JAMA Dermatol, 2015 : 151 : 154-160.
  • 291) Kornmehl H, Singh S, Johnson MA, Armstrong AW : Direct-access online care for the manage-ment of atopic dermatitis : A randomized clinical trial examining patient quality of life, Telemed J E Health, 2017 : 23 : 726-732.
  • 292) van Os-Medendorp H, Koffijberg H, Eland-de Kok PC, et al : E-health in caring for patients with atopic dermatitis : a randomized controlled cost-effectiveness study of internet-guided moni-toring and online self-management training, Br J Dermatol, 2012 : 166 : 1060-1068.
  • 293) Adachi M, Takamasu T, Inuo C : Hyponatremia secondary to severe atopic dermatitis in early infancy. Pediatr Int, 2019 ; 61 : 544-550.
    pubmed
  • 294) 福井次矢, 山口直人監修, 森實敏夫, 吉田雅博, 小島原典子編集 : Minds診療ガイドライン作成の手引き2014, 東京, 医学書院, 2014.
  • 295) 日本緩和医療学会 緩和医療ガイドライン委員会 : 終末期がん患者の輸液療法に関するガイドライン2013年版, 東京, 金原出版, 2013.
  • 296) Gehring W, Gloor M : Treatment of the atopic dermatitis with a water-in-oil emulsion with or without the addition of hydrocortisone-results of a controlled double-blind randomized study using clinical evaluation and bioengineering methods, Z Hautkr, 1996 ; 71 : 554-560.
    pubmed
  • 297) Sears HW, Bailer JW, Yeadon A : Efficacy and safety of hydrocortisone buteprate 0.1% cream in patients with atopic dermatitis, Clin Ther, 1997 ; 19 : 710-719.
  • 298) Lupton ES, Abbrecht MM, Brandon ML : Short-term topical corticosteroid therapy(halcinonide ointment)in the management of atopic dermati-tis, Cutis, 1982 ; 30 : 671-675.
  • 299) Sudilovsky A, Muir JG, Bocobo FC : A compari-son of single and multiple application of halci-nonide cream, Int J Drematol, 1981 ; 20 : 609-613.
  • 300) Wahlgren CF, Hagermark O, Bergstrom R, Hedin B : Evaluation of new method of assessing pruritus and antipruritic drugs, Skin Pharmacol, 1988 ; 1 : 3-13.
    pubmed
  • 301) Lebwohl M : Efficacy and safety of fluticasone propionate ointment, 0.005%, in the treatment of eczema, Cutis, 1996 ; 57(2 Suppl) : 62-68.
  • 302) Breneman D, Fleischer AB Jr, Kaplan D, et al : Clobetasol propionate 0.05% lotion in the treat-ment of moderate to severe atopic dermatitis : a randomized evaluation versus clobetasol propio-nate emollient cream, J Drugs Dermatol, 2005 ; 4 : 330-336.
  • 303) Matheson R, Kempers S, Breneman D, et al : Hydrocortisone butyrate 0.1% lotion in the treat-ment of atopic dermatitis in pediatric subjects, J Drugs Dermatol, 2008 ; 7 : 266-271.
  • 304) Kimball AB, Gold MH, Zib B, et al : Clobetasol propionate emulsion formulation foam 0.05% : review of phase II open-label and phase III ran-domized controlled trials in steroid-responsive dermatoses in adults and adolescents, J Am Acad Dermatol, 2008 ; 59 : 448-454.
  • 305) Nankervis H, Thomas KS, Delamere FM, et al : What is the evidence base for atopic eczema treatments? A summary of published random-ized controlled trials, Br J Dermatol, 2017 ; 176 : 910-927.
  • 306) Bleehen SS, Chu AC, Hamann I, Holden C, Hunter JA, Marks R : Fluticasone propionate 0.05% cream in the treatment of atopic eczema : a multicentre study comparing once-daily treat-ment and once-daily vehicte cream application versus twice-daily treatment, Br J Dermatol, 1995 ; 133 : 592-597.
  • 307) Koopmans B, Andersen BL, Mork NJ, Austad J, Suhonen R, Roders GA : Multicentre randomized double-blind study of locoid lipocream fatty cream twice daily versus locoid lipocream once daily and locobase once daily, J Dermatol Treat, 1995 ; 6 : 103-106.
  • 308) Kerscher MJ, Korting HC, Mehringer L, Matzig R : 0.05% clobetasol 17-propionate cream and ointment but not the corresponding 0.1% triam-cinolone acetonide preparations increase skin surface roughness : a possible dissociation of unwanted epidermal and dermal effects, Skin Pharmacol, 1996 ; 9 : 120-123.
  • 309) Korting HC, Unholzer A, Schafer-Korting M, Tausch I, Gassmueller J, Nietsch KH : Different skin thinning potential of equipotent medi-um-strength glucocorticoids, Skin Pharmacol Appl Skin Physiol, 2002 ; 15 : 85-91.
  • 310) Faergemann J, Christensen O, Sjovall P, et al : An open study of efficacy and safety of long-term treatment with mometasone furoate fatty cream in the treatment of adult patients with atopic dermatitis, J Eur Acad Dermatol Venereol, 2000 ; 14 : 393-396.
    pubmed
  • 311) Eichenfield LF, Tom WL, Chamlin SL, et al : Guidelines of care for the management of atopic dermatitis : section 1. Diagnosis and assessment of atopic dermatitis, J Am Acad Dermatol, 2014 ; 70 : 338-351.
    pubmed
  • 312) Berth-Jones J, Damstra RJ, Golsch S, et al : Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis : randomised, dou-ble blind, parallel group study, BMJ, 2003 ; 326 : 1367.
  • 313) Glazenburg EJ, Wolkerstorfer A, Gerretsen AL, Mulder PG, Oranje AP : Efficacy and safety of fluticasone propionate 0.005% ointment in the long-term maintenance treatment of children with atopic dermatitis : differences between boys and girls? Pediatr Allergy Immunol, 2009 ; 20 : 59-66.
  • 314) Hanifin J, Gupta AK, Rajagopalan R : Intermit-tent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients, Br J Dermatol, 2002 ; 147 : 528-537.
  • 315) Peserico A, Stadtler G, Sebastian M, Fernandez RS, Vick K, Bieber T : Reduction of relapses of atopic dermatitis with methylprednisolone ace-ponate cream twice weekly in addition to main-tenance treatment with emollient : a multicentre, randomized, double-blind, controlled study, Br J Dermatol, 2008 ; 158 : 801-807.
  • 316) Van Der Meer JB, Glazenburg EJ, Mulder PG, Eggink HF, Coenraads PJ : The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Nether-lands Adult Atopic Dermatitis Study Group, Br J Dermatol, 1999 ; 140 : 1114-1121.
  • 317) Schmitt J, von Kobyletzki L, Svensson A, Apfel-bacher C : Efficacy and tolerability of proactive treatment with topical corticosteroids and calci-neurin inhibitors for atopic eczema : systematic review and meta-analysis of randomized con-trolled trials, Br J Dermatol, 2011 ; 164 : 415-428.
  • 318) Hajar T, Leshem YA, Hanifin JM, et al : A sys-tematic review of topical corticosteroid with-drawal("steroid addiction")in patients with atopic dermatitis and other dermatoses, J Am Acad Dermatol, 2015 ; 72 : 541-549. e2.
  • 319) Beck KM, Seitzman GD, Yang EJ, Sanchez IM, Liao W : Ocular co-morbidities of atopic dermati-tis. Part I : Associated ocular diseases. Am J Clin Dermatol, 2019 ; 20 : 797-805.
  • 320) Thyssen JP, Toft PB, Halling-Overgaard AS, Gis-lason GH, Skov L, Egeberg A : Incidence, preva-lence, and risk of selected ocular disease in adults with atopic dermatitis, J Am Acad Dermatol, 2017 ; 77 : 280-286.
  • 321) Igarashi A, Fujita H, Arima K, et al : Health-care resource use and current treatment of adult atopic dermatitis patients in Japan : A retrospec-tive claims database analysis, J Dermatol, 2019 ; 46 : 652-661.
  • 322) Katoh N, Saeki H, Kataoka Y, et al : Atopic der-matitis disease registry in Japanese adult patients with moderate to severe atopic dermati-tis(ADDRESS-J) : Baseline characteristics, treatment history and disease burden, J Dermatol, 2019 ; 46 : 290-300.
  • 323) Wu KK, Borba AJ, Deng PH, Armstrong AW : Association between atopic dermatitis and con-junctivitis in adults : a population-based study in the United States, J Dermatolog Treat, 2019 Sep 2 : 1-5. doi : 10.1080/09546634.2019.1659480. Epub ahead of print.
  • 324) Cowan A, Klauder JV : Frequency of occurrence of cataract in atopic dermatitis, Arch Ophthal, 1950 ; 43 : 759-768.
    pubmed
  • 325) George SM, Karanovic S, Harrison DA, et al : Interventions to reduce Staphylococcus aureus in the management of eczema, Cochrane Datahase Syst Rev, 2019 ; CD003871.
  • 326) Schnopp C, Ring J, Mempel M : The role of anti-bacterial therapy in atopic eczema, Expert Opin Pharmacother, 2010 ; 11 : 929-936.
    pubmed
  • 327) Rastogi S, Patel KR, Singam V, Silverberg JI : Allergic contact dermatitis to personal care products and topical medications in adults with atopic dermatitis, J Am Acad Dermatol, 2018 ; 79 : 1028-1033. e6.
  • 328) 鈴木加余子, 松永佳代子, 矢上晶子ほか : ジャパニーズスタンダードアレルゲン(2008)2013年度・2014年度陽性率, J Environ Dermatol Cutan Allergol, 2017 ; 11 : 234-247.
  • 329) Doss N, Kamoun MR, Dubertret L, et al : Effi-cacy of tacrolimus 0.03% ointment as second-line treatment for children with moderate-to-severe atopic dermatitis : evidence from a randomized, double-blind non-inferiority trial vs. fluticasone 0.005% ointment, Pediatr Allergy Immunol, 2010 ; 21 : 321-329.
  • 330) Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC : Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis : meta-analysis of randomized controlled trials, BMJ, 2005 ; 350 : 516-522.
  • 331) El-Batawy MM, Bosseila MA, Mashaly HM, Hafez VS : Topical calcineurin inhibitors in atopic dermatitis : A systematic review and meta-analysis, J Dermatol Sci, 2009 ; 54 : 76-87.
    pubmed
  • 332) Svesson A, Chambers C, Ganemo A, Mitchell SA : A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis, Curr Med Res Opin, 2011 ; 27 : 1395-1406.
  • 333) Callen J, Chamlin S, Eichenfield LF, et al : A sys-tematic review of the safety of topical therapies for atopic dermatitis, Br J Dermatol, 2007 ; 156 : 203-221.
  • 334) 鳥居薬品株式会社 : コレクチム(R)軟膏0.5% 医薬品インタビューフォーム, 2020年1月(第1版).
  • 335) 大槻マミ太郎, 白ヶ沢智生, 宗 正博, 中川秀己 : 小児のアトピー性皮膚炎に対するタクロリムス軟膏0.03%小児用の長期の安全性と有効性について-長期特定使用成績調査の中間報告-, 日小皮会誌, 2013 ; 32 : 127-137.
  • 336) Margolis DJ, Hoffstad O, Bilker W : Lack of asso-ciation between exposure to topical calcineurin inhibitors and skin cancer in adults, Dermatology, 2007 ; 214 : 289-295.
  • 337) Reitamo S, Rustin M, Harper J, et al : A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients, Br J Dermatol, 2008 ; 159 : 942-951.
  • 338) Arellano FM, Arana A, Wentworth CE, et al : Lymphoma among patients with atopic dermati-tis and/or treated with topical immunosuppres-sants in the United Kingdom, J Allergy Clin Immunol, 2009 ; 123 : 1111-1116.
  • 339) Legendre L, Barnetche T, Mazereeuw-Hautier J, et al : Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment : A systematic review and meta-analysis, J Am Acad Dermatol, 2015 ; 72 : 992-1002.
    pubmed
  • 340) Cury Martins J, Martins C, Aoki V, et al : Topi-cal tacrolimus for atopic dermatitis, Cochrane Database Syst Rev, 2015 ; CD009864.
  • 341) Siegfried EC, Jaworski JC, Kaiser JD, Hebert AA : Systematic review of published trials : long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis, BMC Pediatr, 2016 ; 16 : 75.
    pubmed
  • 342) Castellsague J, Kuiper JG, Pottegard A, et al : A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecroli-mus, and corticosteroids(Joint European Longi-tudinal Lymphoma and Skin Cancer Evaluation-JOELLE study), Clin Epidemiol, 2018 ; 10 : 299-310.
  • 343) Hui RL, Lide W, Chan J, et al : Association between exposure to topical tacrolimus or pimecrolimus and cancers, Ann Pharmacotherapy, 2009 ; 43 : 1956-1963.
    pubmed
  • 344) Siegfried EC, Jaworski JC, Hebert AA : Topical calcineurin inhibitors and lymphoma risk : Evi-dence update with implications for daily prac-tice, Am J Clin Dermatol, 2013 ; 14 : 163-178.
  • 345) 成人型アトピー性皮膚炎研究会 : 成人型アトピー性皮膚炎に対する抗アレルギー剤の有用性の検討 ステロイド外用剤単独とオキサトミド併用の比較試験, 西日皮膚, 1989 ; 51 : 995-1002.
  • 346) 濱田稔夫, 石井正光, 中川浩一ほか : アトピー性皮膚炎に対するテルフェナジンの有用性の臨床的検討 薬効ランクstrongのステロイド外用薬単独とmildの外用薬にテルフェナジン併用との比較試験, 皮膚, 1996 ; 38 : 97-103.
  • 347) 橋爪秀夫, 瀧川雅浩 : アレルギーの臨床に寄せるアトピー性皮膚炎のそう痒に対するロラタジン(クラリチン錠)の臨床効果の検討, アレルギーの臨床, 2004 ; 24 : 1105-1111.
  • 348) 川島 眞, 宮地良樹 : 抗ヒスタミン薬(レボセチリジン)のアトピー性皮膚炎の寛解維持における有用性探索試験 外用剤によるプロアクティブ療法との併用効果検討予備試験, 臨床医薬, 2017 ; 33 : 33-44.
    Medical*Online
  • 349) 川島 眞, 佐藤伸一, 秀 道広, 古江増隆, 宮地良樹 : アトピー性皮膚炎における抗ヒスタミン薬とプロアクティブ外用療法の併用効果の検討, 臨床医薬, 2017 ; 33 : 429-440.
    Medical*Online
  • 350) Kawashima M, Tango T, Noguchi T et al : Addi-tion of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic der-matitis in a 1-week randomized, multi-centre, double-blind, placebo-controlled, parallel-group study, Br J Dermatol, 2003 ; 148 : 1212-1221.
  • 351) 秀 道広, 平田和也, 籠田成靖ほか : アトピー性皮膚炎患者のそう痒に対するルパタジンの長期有用性-皮膚疾患に伴うそう痒を有する患者を対象にした国内第III相臨床試験のpost hoc解析-. アレルギー, 2020 ; 69 : 174-183.
    Medical*Online
  • 352) Peserico A, Stadtler G, Sebastian M, Suarez Fer-nandez R, Vick K, Bieber T : Reduction of relapses of atopic dermatitis with methylpred-nisolone aceponate cream twice weekly in addi-tion to maintenance treatment with emollient : a multicentre, randomized, double-blind, controlled study, Br J Dermatol, 2008 ; 158 : 801-807.
  • 353) Hanifin J, Gupta AK, Rajagopalan R : Intermit-tent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients, Br J Dermatol, 2002 ; 147 : 528-537.
  • 354) Berth-Jones J, Damstra RJ, Golsch S, et al : Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis : randomised, dou-ble blind, parallel group study, BMJ, 2003 ; 326 : 1367.
  • 355) Glazenburg EJ, Wolkerstorfer A, Gerretsen AL, Mulder PG, Oranje AP : Efficacy and safety of fluticasone propionate 0.005% ointment in the long-term maintenance treatment of children with atopic dermatitis : differences between boys and girls? Pediatr Allergy Immunol, 2009 ; 20 : 59-66.
  • 356) Van Der Meer JB, Glazenburg EJ, Mulder PG, Eggink HF, Coenraads PJ : The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Nether-lands Adult Atopic Dermatitis Study Group, Br J Dermatol, 1999 ; 140 : 1114-1121.
  • 357) Rubio-Gomis E, Martinez-Mir I, Morales-Olivas FJ, et al : Fluticasone in mild to moderate atopic dermatitis relapse : A randomized controlled trial, Allergol Immunopathol(Madr), 2018 ; 46 : 378-384.
    pubmed
  • 358) Liu L, Ong G : A randomized, open-label study to evaluate an intermittent dosing regimen of fluti-casone propionate 0.05% cream in combination with regular emollient skin care in reducing the risk of relapse in pediatric patients with stabi-lized atopic dermatitis, J Dermatolog Treat, 2018 ; 29 : 501-509.
  • 359) Fukuie T, Hirakawa S, Narita M, et al : Potential preventive effects of proactive therapy on sensi-tization in moderate to severe childhood atopic dermatitis : A randomized, investigator-blinded, controlled study, J Dermatol, 2016 ; 43 : 1283-1292.
  • 360) Chung BY, Kim HO, Kim JH, Cho SI, Lee CH, Park CW : The proactive treatment of atopic dermatitis with tacrolimus ointment in Korean patients : a comparative study between once-weekly and thrice-weekly applications, Br J Der-matol, 2013 ; 168 : 908-910.
  • 361) Poole CD, Chambers C, Sidhu MK, Currie CJ : Health-related utility among adults with atopic dermatitis treated with 0.1% tacrolimus oint-ment as maintenance therapy over the long term : findings from the Protopic CONTROL study, Br J Dermatol, 2009 ; 161 : 1335-1340.
  • 362) Thaci D, Reitamo S, Gonzalez Ensenat MA, et al : Proactive disease management with 0.03% tacrolimus ointment for children with atopic der-matitis : results of a randomized, multicentre, comparative study, Br J Dermatol, 2008 ; 159 : 1348-1356.
  • 363) Wollenberg A, Reitamo S, Girolomoni G, et al : Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment, Allergy, 2008 ; 63 : 742-750.
  • 364) Breneman D, Fleischer AB Jr, Abramovits W, et al : Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis : a randomized comparison of 3-times-weekly applications of tacrolimus ointment ver-sus vehicle, J Am Acad Dermatol, 2008 ; 58 : 990-999.
  • 365) Wilhelm KP, Scholermann A : Efficacy and toler-ability of a topical preparation containing 10% urea in patients with atopic dermatitis, Aktuel Dermatol, 1998 ; 24 : 37-38.
  • 366) Loden M, Andersson AC, Andersson C, et al : Instrumental and dermatologist evaluation of the effect of glycerine and urea on dry skin in atopic dermatitis, Skin Res Technol, 2001 ; 7 : 209-213.
    pubmed
  • 367) Boralevi F, Saint Aroman M, Delarue A, et al : Long-term emollient therapy improves xerosis in children with atopic dermatitis, J Eur Acad Der-matol Venereol, 2014 ; 28 : 1456-1462.
  • 368) Breternitz M, Kowatzki D, Langenauer M, Elsner P, Fluhr JW : Placebo-controlled, dou-ble-blind, randomized, prospective study of a glycerol-based emollient on eczematous skin in atopic dermatitis : biophysical and clinical evalu-ation, Skin Pharmacol Physiol, 2008 ; 21 : 39-45.
  • 369) 濱田 学, 行徳隆裕, 佐藤さおりほか : アトピー性皮膚炎患者に対するツバキ油スプレーの安全性及び有用性の検討, 西日皮膚, 2008 ; 70 : 213-218.
  • 370) 松中 浩, 阿部淑子, 大江昌彦, 錦織千佳子, 宮地良樹 : オリゴマリン(R)(濃縮海水ミネラル成分)のアトピックドライスキンへの使用経験, 皮膚の科学, 2004 ; 3 : 73-83.
  • 371) Szczepanowska J, Reich A, Szepietowski LC : Emollients improve treatment results with topi-cal corticosteroids in childhood atopic dermati-tis : a randomized comparative study, Pediatr Allergy Immunol, 2008 ; 19 : 614-618.
  • 372) Wiren K, Nohlgard C, Nyberg F, et al : Treat-ment with a barrier-strengthening moisturizing cream delays relapse of atopic dermatitis : a prospective and randomized controlled clinical trial, J Eur Acad Dermatol Venereol, 2009 ; 23 : 1267-1272.
  • 373) Tiplica GS, Boralevi F, Konno P, et al : The reg-ular use of an emollient improves symptoms of atopic dermatitis in children : a randomized con-trolled study, J Eur Acad Dermatol Venereol, 2018 ; 32 : 1180-1187.
  • 374) Angelova-Fischer I, Rippke F, Richter D, et al : Stand-alone emollient treatment reduces flares after discontinuation of topical steroid treatment in atopic dermatitis : A double-blind, randomized, vehicle-controlled, left-right comparison study, Acta Derm Venereol, 2018 ; 98 : 517-523.
    pubmed
  • 375) Leung DY : New insights into atopic dermati-tis : role of skin barrier and immune dysregula-tion, Allergol Int, 2013 ; 62 : 151-161.
  • 376) Loden M : Role of topical emollients and moistur-izers in the treatment of dry skin barrier disor-ders, Am J Clin Dermatol, 2003 ; 4 : 771-788.
  • 377) Dissanayake E, Tani Y, Shimojo N, at al : Skin care and synbiotics for prevention of atopic der-matitis and food allergy in newborn infants : A 2x2 factorial, randomized, non-treatment con-trolled trial, Int Arch Allergy Immunol, 2019 ; 180 : 202-211.
  • 378) Chalmers JR, Haines RH, Bradshaw LE, et al : Daily emollient during infancy for prevention of eczema : the BEEP randomised controlled trial, Lancet, 2020 ; 395 : 962-972.
    pubmed
  • 379) Skjerven HO, Rehbinder EM, Vettukattil R, et al : Skin emollient and early complementary feeding to prevent infant atopic dermatitis(Pre-ventADALL) : a factorial, multicentre, clus-ter-randomised trial, Lancet, 2020 ; 395 : 951-961.
  • 380) Hon KL, Leung TF, Wong Y, So HK, Li AM, Fok TF : A survey of bathing and showering prac-tices in children with atopic eczema, Clin Exp Dermatol, 2005 ; 30 : 351-354.
  • 381) Heyer GR, Hornstein OP : Recent studies of cuta-neous nociception in atopic and non-atopic sub-jects, J Dermatol, 1999 ; 26 : 77-86.
  • 382) 亀好良一, 田中稔彦, 望月 満ほか : アトピー性皮膚炎に対する学校でのシャワー浴の効果, アレルギー, 2008 ; 57 : 130-137.
    Medical*Online
  • 383) Mochizuki H, Muramatsu R, Tadaki H, Mizuno T, Arakawa H, Morikawa A : Effects of skin care with shower therapy on children with atopic dermatitis in elementary schools, Pediatr Derma-tol, 2008 ; 26 : 223-225.
  • 384) Murota H, Takahashi A, Nishioka M, et al : Showering reduces atopic dermatitis in elemen-tary school students, Eur J Dermatol, 2010 ; 20 : 410-411.
  • 385) 前田七瀬, 吉田直美, 西野 洋, 片岡葉子 : 重症成人アトピー性皮膚炎患者における血清TARCの臨床的意義, J Environ Dermatol Cutan Allergol, 2011 ; 5 : 27-35.
    Medical*Online
  • 386) Kakinuma T, Nakamura K, Wakugawa M, et al : Thymus and activation-regulated chemokine in atopic dermatitis : Serum thymus and activa-tion-regulated chemokine level is closely related with disease activity, J Allergy Clin Immunol, 2001 ; 107 : 535-541.
  • 387) Hijnen D, De Bruin-Weller M, Oosting B, et al : Serum thymus and activation-regulated chemok-ine(TARC)and cutaneous T cell-attracting chemokine(CTACK)levels in allergic diseases : TARC and CTACK are disease-specific markers for atopic dermatitis, J Allergy Clin Immunol, 2004 ; 113 : 334-340.
  • 388) Thijs J, Krastev T, Weidinger S, et al : Biomark-ers for atopic dermatitis : a systemic review and meta-analysis, Curr Opin Allergy Clin Immunol, 2015 ; 15 : 453-460.
  • 389) 宮本和典 : 血清TARC検査の迅速・院内測定を可能としたHISCL TARC試薬, アレルギーの臨床, 2016 ; 1155-1157.
  • 390) Campbell B, De'Ambrosis B : Squamous cell car-cinoma antigen in patients with cutaneous disor-ders, J Am Acad Dermatol, 1990 ; 22 : 639-642.
  • 391) Horiuchi Y, Tsukahara T, Otoyama K : Immuno-histochemical study of elevated expression of squamous cell carcinoma(SCC)-related antigens in erythrodermic epidermis, J Dermatol, 1994 ; 21 : 67-72.
  • 392) Kawashima H, Nishimata S, Kashiwagi Y, et al : Squamous cell carcinoma-related antigen in chil-dren with atopic dermatitis, Pediatr Int, 2000 ; 42 : 448-450.
  • 393) Mitsuishi K, Nakamura T, Sakata Y, et al : The Squamous cell carcinoma antigens as relevant biomarkers of atopic dermatitis, Clin Exp Allergy, 2005 ; 35 : 1327-1333.
    pubmed
  • 394) Sowden JM, Berth-Jones J, Ross JS, et al : Dou-ble-blind, controlled, crossover study of cyclospo-rin in adults with severe refractory atopic dermatitis, Lancet, 1991 ; 338 : 137-140.
  • 395) Harper JI, Ahmed I, Barclay G, et al : Cyclospo-rin for severe childhood atopic dermatitis : short course versus continuous therapy, Br J Dermatol, 2000 ; 142 : 52-58.
  • 396) Czech W, Brautigam M, Weidinger G, et al : A body-weight-independent dosing regimen of cyc-losporine microemulsion is effective in severe atopic dermatitis and improves the quality of life, J Am Acad Dermatol, 2000 ; 42 : 653-659.
  • 397) ネオーラルによるアトピー性皮膚炎治療研究会 : 成人の重症アトピー性皮膚炎患者に対するシクロスポリンMEPCとプラセボとの比較試験 : 多施設共同, ランダム化, 二重盲検, 並行群間比較試験, 臨皮, 2009 ; 63 : 73-82.
  • 398) 森脇真一 : アトピー性皮膚炎患者への紫外線に関する生活指導のポイントを教えて下さい, 加藤則人編 : エキスパートが答える!アトピー性皮膚炎Q&A55, 東京, 診断と治療社, 2014, 121-123.
  • 399) Juzeniene A, Moan J : Beneficial effects of UV radiation other than via vitamin D production, Dermatoendocrinol, 2012 ; 4 : 109-117.
    pubmed
  • 400) Patrizi A, Raone B, Ravaioli GM : Management of atopic dermatitis : safety and efficacy of pho-totherapy, Clin Cosmet Investig Dermatol, 2015 ; 8 : 511-520.
  • 401) Archier E, Devaux S, Castela E, et al : Carcino-genic risks of psoralen UV-A therapy and nar-rowband UV-B therapy in chronic plaque psoriasis : a systematic literature review, J Eur Acad Dermatol Venereol, 2012 ; 26 : 22-31.
  • 402) Man I, Crombie IK, Dawe RS, et al : The photo-carcinogenic risk of narrowband UVB(TL-01)phototherapy : early follow-up data, Br J Dermatol, 2005 ; 152 : 755-757.
  • 403) Osmancevic A, Gillstedt M, Wennberg AM, et al : The risk of skin cancer in psoriasis patients treated with UVB therapy, Acta Derm Venereol, 2014 ; 94 : 425-430.
    pubmed
  • 404) Hearn RM, Kerr AC, Rahlm KF, et al : Incidence of skin cancers in 3867 patients treated with nar-row-band ultraviolet B phototherapy, Br J Derma-tol, 2008 ; 159 : 931-935.
  • 405) Katoh N, Kataoka Y, Saeki H, et al : Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis : a subanal-ysis of three clinical trials, Br J Dermatol, 2020 ; 183 : 39-51.
  • 406) Fleming P, Drucker AM : Risk of infection in patients with atopic dermatitis treated with dup-ilumab : a meta-analysis of randomized con-trolled trials, J Am Acad Dermatol, 2018 ; 78 : 62-69.
  • 407) Eichenfield LF, Bieber T, Beck LA, et al : Infec-tions in dupilumab clinical trials in atopic derma-titis : a comprehensive pooled analysis, Am J Clin Dermatol, 2019 ; 20 : 443-456.
  • 408) Tan HY, Zhang AL, Chen D, Xue CC, Lenon GB : Chinese herbal medicine for atopic dermati-tis : a systematic review, J Am Acad Dermatol, 2013 ; 69 : 295-304.
  • 409) Hon KL, Leung TF, Ng PC, et al : Efficacy and tolerability of a Chinese herbal medicine concoc-tion for treatment of atopic dermatitis : a ran-domized, double-blind, placebo-controlled study, Br J Dermatol, 2007 ; 157 : 357-363.
  • 410) Gu SX, Mo X, Zhang AL, et al : A Chinese herbal medicine preparation(Pei Tu Qing Xin)for children with moderate-to-severe atopic eczema : a pilot randomized controlled trial, Br J Dermatol, 2018 ; 179 : 1404-1405.
    pubmed
  • 411) Liu J, Mo X, Wu D, et al : Efficacy of a Chinese herbal medicine for the treatment of atopic der-matitis : a randomised controlled study, Comple-ment Ther Med, 2015 ; 23 : 644-651.
  • 412) 柳原茂人 : アトピー性皮膚炎における漢方製剤のEBM, 日本東洋心身医学研究, 2019 ; 34 : 68-72.
    Medical*Online
  • 413) Holm L, Bengtsson A, van Hage-Hamsten M, Ohman S, Scheynius A : Effectiveness of occlu-sive bedding in the treatment of atopic dermati-tis--a placebo-controlled trial of 12 months' duration, Allergy, 2001 ; 56 : 152-158.
  • 414) Ricci G, Patrizi A, Specchia F, et al : Effect of house dust mite avoidance measures in children with atopic dermatitis, Br J Dermatol, 2000 ; 143 : 379-384.
    pubmed
  • 415) Friedmann PS, Tan BB : Mite elimination--clini-cal effect on eczema, Allergy, 1998 ; 53(48 Suppl) : 97-100.
  • 416) Tan BB, Weald D, Strickland I, Friedmann PS : Double-blind controlled trial of effect of house-dust-mite allergen avoidance on atopic dermati-tis, Lancet, 1996 ; 347 : 15-18.
  • 417) Sanda T, Yasue T, Oohashi M, Yasue A : Effec-tiveness of house dust-mite allergen avoidance through clean room therapy in patients with atopic dermatitis, J Allergy Clin Immunol, 1992 ; 89 : 653-657.
  • 418) Oosting AJ, de Bruin-Weller MS, Terreehorst I, et al : Effect of mattress encasings on atopic der-matitis outcome measures in a double-blind, pla-cebo-controlled study : the Dutch mite avoidance study, J Allergy Clin Immunol, 2002 ; 110 : 500-506.
  • 419) Gutgesell C, Heise S, Seubert S, et al : Dou-ble-blind placebo-controlled house dust mite con-trol measures in adult patients with atopic dermatitis, Br J Dermatol, 2001 ; 145 : 70-74.
  • 420) Nankervis H, Pynn EV, Boyle RJ, et al : House dust mite reduction and avoidance measures for treating eczema, Cochrane Database Syst Rev, 2015 ; CD008426.
    pubmed
  • 421) 南部光彦 : アレルギー児における屋内アレルゲン対策, 日小ア会誌, 2010 ; 24 : 203-216.
  • 422) Atherton DJ, Sewell M, Soothill JF, Wells RS, Chilvers CE : A double-blind controlled cross-over trial of an antigen-avoidance diet in atopic eczema, Lancet, 1978 ; 1 : 401-403.
  • 423) Neild VS, Marsden RA, Bailes JA, Bland JM : Egg and milk exclusion diets in atopic eczema, Br J Dermatol, 1986 ; 114 : 117-123.
    pubmed
  • 424) Cant AJ, Bailes JA, Marsden RA, Hewitt D : Effect of maternal dietary exclusion on breast fed infants with eczema : two controlled studies, Br Med J(Clin Res Ed), 1986 ; 293 : 231-233.
    pubmed
  • 425) Lever R, MacDonald C, Waugh P, Aitchison T : Randomised controlled trial of advice on an egg exclusion diet in young children with atopic eczema and sensitivity to eggs, Pediatr Allergy Immunol, 1998 ; 9 : 13-19.
  • 426) Niggemann B, Binder C, Dupont C, Hadji S, Arvola T, Isolauri E : Prospective, controlled, multi-center study on the effect of an amino-ac-id-based formula in infants with cow's milk allergy/intolerance and atopic dermatitis, Pediatr Allergy Immunol, 2001 ; 12 : 78-82.
  • 427) Isolauri E, Sutas Y, Makinen-Kiljunen S, Oja SS, Isosomppi R, Turjanmaa K : Efficacy and safety of hydrolyzed cow milk and amino acid-derived formulas in infants with cow milk allergy, J Pedi-atr, 1995 ; 127 : 550-557.
  • 428) Mabin DC, Sykes AE, David TJ : Controlled trial of a few foods diet in severe atopic dermatitis, Arch Dis Child, 1995 ; 73 : 202-207.
    pubmed
  • 429) Munkvad M, Danielsen L, Hoj L, et al : Anti-gen-free diet in adult patients with atopic der-matitis. A double-blind controlled study. Acta Derm-Venereol, 1984 ; 64 : 524-528.
  • 430) Leung TF, Ma KC, Cheung LT, et al : A ran-domized, single-blind and crossover study of an amino acid-based milk formula in treating young children with atopic dermatitis, Pediatr Allergy Immunol, 2004 ; 15 : 558-561.
  • 431) Lack G, Fox D, Northstone K, Golding J : Factors associated with the development of peanut allergy in childhood, N Engl J Med, 2003 ; 348 : 977-985.
    pubmed
  • 432) Hourihane JO, Aiken R, Briggs R, et al : The impact of government advice to pregnant moth-ers regarding peanut avoidance on the preva-lence of peanut allergy in United Kingdom children at school entry, J Allergy Clin Immunol, 2007 ; 119 : 1197-1202.
  • 433) Dean T, Venter C, Pereira B, et al : Government advice on peanut avoidance during pregnancy-is it followed correctly and what is the impact on sensitization? J Hum Nutr Diet, 2007 ; 20 : 95-99.
    pubmed
  • 434) Herrmann ME, Dannemann A, Gruters A, et al : Prospective study on the atopy preventive effect of maternal avoidance of milk and eggs during pregnancy and lactation, Eur J Pediatr, 1996 ; 155 : 770-774.
    pubmed
  • 435) Zeiger RS, Heller S : The development and pre-diction of atopy in high-risk children : Follow-up at age seven years in a prospective randomized study of combined maternal and infant food allergen avoidance, J Allergy Clin Immunol, 1995 ; 95 : 1179-1190.
  • 436) Arshad SH, Bateman B, Sadeghnejad A, Gant C, Matthews SM : Prevention of allergic disease during childhood by allergen avoidance : the Isle of Wight prevention study, J Allergy Clin Immu-nol, 2007 ; 119 : 307-313.
  • 437) Hattevig G, Sigurs N, Kjellman B : Effects of maternal dietary avoidance during lactation on allergy in children at 10 years of age, Acta Paedi-atr, 1999 ; 88 : 7-12.
  • 438) Frank L, Marian A, Visser M, Weinberg E, Pot-ter PC : Exposure to peanuts in utero and in infancy and the development of sensitization to peanut allergens in young children, Pediatr Allergy Immunol, 1999 ; 10 : 27-32.
  • 439) Sicherer SH, Wood RA, Stablein D, et al : Mater-nal consumption of peanut during pregnancy is associated with peanut sensitization in atopic infants, J Allergy Clin Immunol, 2010 ; 126 : 1191-1197.
  • 440) Greer FR, Sicherer SH, Burks AW : The effects of early nutritional interventions on the develop-ment of atopic disease in infants and children : The role of maternal dietary restriction, breast-feeding, hydrolyzed formulas, and timing of introduction of allergenic complementary foods, Pediatrics, 2019 ; 143 : e20190281.
  • 441) Bedard A, Northstone K, Henderson AJ, et al : Maternal intake of sugar during pregnancy and childhood respiratory and atopic outcomes, Eur Respir J, 2017 ; 50 : 1700073.
    pubmed
  • 442) Pretorius RA, Bodinier M, Prescott SL, et al : Maternal fiber dietary intakes during pregnancy and infant allergic disease, Nutrients, 2019 ; 11 : 1767.
  • 443) Cuello-Garcia CA, Brozek JL, Fiocchi A, et al : Probiotics for the prevention of allergy : A sys-tematic review and meta-analysis of randomized controlled trials, J Allergy Clin Immunol, 2015 ; 136 : 952-961.
  • 444) Li L, Han Z, Niu X, et al : Probiotic supplementa-tion for prevention of atopic dermatitis in infants and children : A systematic review and meta-analysis, Am J Clin Dermatol, 2019 ; 20 : 367-377.
  • 445) Mansfield JA, Bergin SW, Cooper JR, Olsen CH : Comparative probiotic strain efficacy in the pre-vention of eczema in infants and children : a systematic review and meta-analysis, Mil Med, 2014 ; 179 : 580-592.
  • 446) Osborn DA, Sinn JK : Probiotics in infants for prevention of allergic disease and food hyper-sensitivity, Cochrane Datahase Syst Rev, 2007 ; CD006475.
  • 447) Osborn DA, Sinn JK : Prebiotics in infants for prevention of allergy, Cochrane Database Syst Rev, 2013 ; CD006474.
    pubmed
  • 448) Sanchez J, Sanchez MR, Macias-Weinmann A, et al : Systematic review about 10 interventions in dermatitis. A document from the Latin Ameri-can Society of Allergy, Asthma, and Immunol-ogy, Rev Alerg Mex, 2019 ; 66 : 426-455.
  • 449) Szajewska H, Horvath A : Lactobacillus rhamno-sus GG in the primary prevention of eczema in children : A systematic review and meta-analy-sis, Nutrients, 2018 ; 10 : 1319.
  • 450) Zuccotti G, Meneghin F, Aceti A, et al : Probiotics for prevention of atopic diseases in infants : sys-tematic review and meta-analysis, Allergy, 2015 ; 70 : 1356-1371.
  • 451) Kuitunen M, Kukkonen K, Juntunen-Backman K, et al : Probiotics prevent IgE-associated allergy until age 5 years in cesarean-delivered children but not in the total cohort, J Allergy Clin Immunol, 2009 ; 123 : 335-341.
  • 452) Simpson MR, Dotterud CK, Storro O, Johnsen R, Oien T : Perinatal probiotic supplementation in the prevention of allergy related disease : 6 year follow up of a randomised controlled trial, BMC Dermatol, 2015 ; 15 : 13.
    pubmed
  • 453) West CE, Hammarstrom ML, Hernell O : Probiot-ics in primary prevention of allergic disease--fol-low-up at 8-9 years of age, Allergy, 2013 ; 68 : 1015-1020.
  • 454) 岡野伸二, 高橋博之, 矢野貴彦ほか : 小学1年生の学童が有するアトピー性皮膚炎を含めた皮膚病変の5年後の予後調査. 広島県安佐地区での検討, 日医雑誌, 2006 ; 135 : 97-103.
  • 455) 有馬孝恭, 河野陽一 : アトピー性皮膚炎有症率調査の現状, アレルギーの臨床, 2009 ; 29 : 581-587.
  • 456) 渋谷紀子, 斉藤恵美子 : 抗原感作およびアレルギー疾患の自然経過-4歳までの出生コホート研究, 日小ア誌, 2015 ; 29 : 284-93.
    Medical*Online
  • 457) Hua TC, Hwang CY, Chen YJ, et al : The natural course of early-onset atopic dermatitis in Tai-wan : a population-based cohort study, Br J Der-matol, 2014 ; 170 : 130-135.
  • 458) von Kobyletzki LB, Bomehag CG, Breeze E, et al : Factors associated with remission of eczema in children : a population-based follow-up study, Acta Derm Venereol, 2014 ; 94 : 179-184.
  • 459) Wan J, Mitra N, Hoffstad OJ, et al : Longitudinal atopic dermatitis control and persistent vary with timing of disease onset in children : a cohort study, J Am Acad Dermatol, 2019 ; 81 : 1292-1299.
    pubmed
  • 460) Seto A, Einarson T, Koren G : Pregnancy out-come following first trimester exposure to anti-histamines : meta-analysis, Am J Perinatol, 1997 ; 14 : 119-124.
  • 461) Etwel F, Faught LH, Rieder MJ, Koren G : The risk of adverse pregnancy outcome after first trimester exposure to H1 antihistamines : A sys-tematic review and meta-analysis, Drug Saf, 2017 ; 40 : 121-32.
  • 462) Schwarz EB, Moretti ME, Nayak S, Koren G : Risk of hypospadias in offspring of women using loratadine during pregnancy : a systematic review and meta-analysis, Drug Saf, 2008 ; 31 : 775-788.
    pubmed
  • 463) Zuberbier T, Aberer W, Asero R, et al : The EAACI/GA (2) LEN/EDF/WAO guideline for the definition, classification, diagnosis and man-agement of urticaria. The 2017 revision and update, Allergy, 2018 ; 73 : 1393-1414.
  • 464) Andersson NW, Poulsen HE, Andersen JT : Desloratadine use during pregnancy and risk of adverse fetal outcomes : A nationwide cohort study, J Allergy Clin Immunol Pract, 2020 ; 8 : 1598-1605.
    pubmed
  • 465) Golembesky A, Cooney M, Boev R, Schlit AF, Bentz JWG : Safety of cetirizine in pregnancy, J Obstet Gynaecol, 2018 ; 38 : 940-945.
    pubmed
  • 466) Weber-Schoendorfer C, Schaefer C : The safety of cetirizine during pregnancy. A prospective observational cohort study, Reprod Toxicol, 2008 ; 26 : 19-23.
  • 467) Andersson NW, Torp-Pedersen C, Andersen JT : Association between fexofenadine use during pregnancy and fetal outcomes, JAMA Pediatr, 2020 : 174 : e201316.
  • 468) Hansen C, Desrosiers TA, Wisniewski K, Strick-land MJ, Werler MM, Gilboa SM : Use of antihis-tamine medications during early pregnancy and selected birth defects : The national birth defects prevention study, 1997-2011, Birth Defects Res, 2020 ; 112 : 1234-1252.
  • 469) Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G : Prospective follow-up of adverse reac-tions in breast-fed infants exposed to maternal medication, Am J Obstet Gynecol, 1993 ; 168 : 1393-1399.
  • 470) Hilbert J, Radwanski E, Affrime MB, Perentesis G, Symchowicz S, Zampaglione N : Excretion of loratadine in human breast milk, J Clin Pharmacol, 1988 ; 28 : 234-239.
    pubmed
  • 471) Lucas BD Jr, Purdy CY, Scarim SK, Benjamin S, Abel SR, Hilleman DE : Terfenadine pharmacoki-netics in breast milk in lactating women, Clin Pharmacol Ther, 1995 ; 57 : 398-402.
  • 472) Hamann CR, Egeberg A, Wollenberg A, Gislason G, Skov L, Thyssen JP : Pregnancy complica-tions, treatment characteristics and birth out-comes in women with atopic dermatitis in Denmark, J Eur Acad Dermatol Venereol, 2019 : 33 : 577-587.
  • 473) Inuzuka Y, Natsume O, Matsunaga M, et al : Washing with water alone versus soap in main-taining remission of eczema, Pediatr Int, 2020 ; 62 : 663-668.
  • 474) White MI, Jenkinson DM, Lloyd DH : The effect of washing on the thickness of the stratum cor-neum in normal and atopic individuals, Br J Der-matol, 1987 ; 116 : 525-530.
  • 475) Ananthapadmanabhan KP, Moore DJ, Subra-manyan K, Misra M, Meyer F : Cleansing with-out compromise : the impact of cleansers on the skin barrier and the technology of mild cleans-ing, Dermatol Ther, 2004 ; 17(Suppl 1) : 16-25.
  • 476) 城市幹恵, 西田文子, 大畑典恵 : 沐浴剤・ボディソープ・泡ボディソープを使用した陰部洗浄の有効性, 日本看護学会論文集 : 看護総合, 2014 ; 44 : 52-55.
  • 477) 山口規容子 : 周産期の薬物療法 新生児の沐浴剤, 周産期医学, 1995 ; 25 : 405-407.
  • 478) 高橋悦二郎, 鈴木 洋, 山本一哉 : 小児科からみたスキンケア 新生児沐浴時における液体沐浴剤使用群と石鹸使用群との比較検討, 日小皮会誌 1990 ; 9 : 204-212.
  • 479) 名城三幸, 千葉真純, 中田朋子, 石橋宏子, 増田 栄, 善家トシコ : 沐浴剤の皮膚乾燥予防効果の検討 沐浴剤と更湯を用いた全身清拭・足浴後の皮膚角質水分量の測定より, 葦, 2007 ; 38 : 149-151.
  • 480) Lavender T, Bedwell C, Roberts SA, et al : Ran-domized, controlled trial evaluating a baby wash product on skin barrier function in healthy, term neonates, J Obstet Gynecol Neonatal Nurs, 2013 ; 42 : 203-214.
  • 481) 泉沢誠子, 竹井幸江, 田辺ミツイほか : 各種沐浴剤の比較検討について, 助産婦雑誌, 1976 ; 30 : 357-361.
  • 482) 川井田直子, 上村真奈美, 喜田早苗ほか : 新生児期から始めるスキンケア, チャイルド ヘルス, 2016 ; 19 : 935-938.
    Medical*Online
  • 483) Maarouf M, Hendricks AJ, Shi VY : Bathing additives for atopic dermatitis-A systematic review, Dermatitis, 2019 ; 30 : 191-197.
    pubmed
  • 484) Rudikoff D, Lebwohl M : Atopic dermatitis, Lan-cet, 1998 ; 351 : 1715-1721.
  • 485) Sugimoto K, Kuroki H, Kanazawa M, et al : New successful treatment with disinfectant for atopic dermatitis, Dermatology, 1997 ; 195(Suppl 2) : 62-68.
  • 486) 植西敏浩, 上原正巳 : ポビドンヨード液消毒の評価, 皮膚臨床, 1998 ; 40(特38) : 984-987.
  • 487) 飯島茂子, 倉持美也子 : 10%ポビドンヨード液による術後の接触皮膚炎, 日皮会誌, 1999 ; 109 : 1029-1041.
  • 488) Pedrosa C, Costa H, Oliveira G Romariz J, Praca F : Anaphylaxis to povidone in a child, Pediatr Allergy Immunol, 2005 ; 16 : 361-362.
  • 489) Myles IA, Earland NJ, Anderson ED, et al : First-in-human topical microbiome transplanta-tion with Roseomonas mucosa for atopic dermatitis, JCI Insight, 2018 ; 3 : e120608
  • 490) Wong SM, Ng TG, Baba R : Efficacy and safety of sodium hypochlorite(bleach)baths in patients with moderate to severe atopic dermatitis in Malaysia, J Dermatol, 2013 ; 40 : 874-880.
    pubmed
  • 491) Huang JT, Abrams M, Tlougan B, Rademaker A, Paller AS : Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases dis-ease severity, Pediatrics, 2009 ; 123 : e808-e814.
  • 492) Hon KL, Tsang YCK, Lee VWY, et al : Efficacy of sodium hypochlorite(bleach)baths to reduce Staphylococcus aureus colonization in childhood onset moderate-to-severe eczema : A random-ized, placebo-controlled cross-over trial, J Derma-tolog Treat, 2016 ; 27 : 156-162.
  • 493) Shi VY, Foolad N, Ornelas JN, et al : Comparing the effect of bleach and water baths on skin bar-rier function in atopic dermatitis : A split-body randomized controlled trial, Br J Dermatol, 2016 ; 175 : 212-214.
  • 494) 佐々木りか子 : 皮膚アレルギー : 集団生活における小児アトピー性皮膚炎の管理, アレルギー, 2016 ; 65 : 974-980.
    Medical*Online
  • 495) Biniek K, Levi K, Dauskardt RH : Solar UV radi-ation reduces the barrier function of human skin, Proc Natl Acad Sci USA, 2012 ; 109 : 17111-17116.
  • 496) Nin M, Katoh N, Kokura S, Handa O, Yoshikawa T, Kishimoto S : Dichotomous effect of ultravio-let B on the expression of corneodesmosomal enzymes in human epidermal keratinocytes, J Dermatol Sci, 2009 ; 54 : 17-24.
  • 497) Deguchi H, Danno K, Sugiura H, Uehara M : Sun exposure is an aggravating factor responsible for the recalcitrant facial erythema in adult patients with atopic dermatitis, Dermatology, 2002 ; 204 : 23-28.
    pubmed
  • 498) 内田美香, 三木和洋, 三井 司, 二石裕佳子, 松本元伸, 山本一哉 : 小児のアトピー性皮膚炎患者に対するSSP UVケアクリームの有用性評価について, 日小皮会誌, 2003 ; 22 : 179-185.
  • 499) 上野真紀子, 高山かおる, 安原美帆, 横関博雄 : 低刺激性サンスクリーン剤の敏感肌患者への使用経験, アレルギー・免疫, 2016 ; 23 : 1129-1136
  • 500) Pelucchi C, Galeone C, Bach JF, La Vecchia C, Chatenoud L : Pet exposure and risk of atopic dermatitis at the pediatric age : a meta-analysis of birth cohort studies, J Allergy Clin Immunol, 2013 ; 132 : 616-622.
    pubmed
  • 501) Stelmach I, Bobrowska-Korzeniowska M, Smejda K, et al : Risk factors for the development of atopic dermatitis and early wheeze, Allergy Asthma Proc, 2014 ; 35 : 382-389.
    pubmed
  • 502) Zirngibl A, Franke K, Gehring U, et al : Expo-sure to pets and atopic dermatitis during the first two years of life. A cohort study, Pediatr Allergy Immunol, 2002 ; 13 : 394-401.
  • 503) Yonekura Y, Katayama I, Murota H : Seropreva-lence of cat-and dog-specific IgEs in atopic der-matitis without history of pet parenting, J Cutan Immunol Allergy, 2018 ; 1 : 149-151.
はじめての方へ
個人／法人会員登録のご案内